Paris, February 7, 2019
Sanofi delivers 2018 business EPS growth of 5.1% at CER
| Q4 2018 | Change | Change at CER | 2018 | Change | Change at CER | |
| IFRS net sales reported | €8,997m | +3.5% | +3.9% | €34,463m | -1.7% | +2.5% |
| IFRS net income reported | €254m | +101.6% | - | €4,306m | -48.8%(2) | - |
| IFRS EPS reported | €0.20 | +100.0% | - | €3.45 | -48.5%(2) | - |
| Business net income(1) | €1,364m | +2.9% | +4.3% | €6,819m | -1.8% | +4.2% |
| Business EPS(1) | €1.10 | +3.8% | +4.7% | €5.47 | -0.9% | +5.1% |
| Fourth-quarter sales(3) growth driven by Specialty Care and Vaccines Net sales were €8,997 million, an increase of 3.5% on a reported basis, 3.9%(3) at CER and 2.6% at CER/CS (4). Sanofi Genzyme sales were up 37.4% (16.1% at CER/CS(4)), led by Immunology and Rare Blood Disorder franchises. Vaccines sales increased 9.7%, driven by successful influenza differentiation strategy and Menactra®. CHC sales increased 1.9%, supported by Emerging Markets. DCV(5) GBU sales were down 11.3%; Global Diabetes franchise sales declined 10.5% in line with 2015-2018 guidance. Emerging Markets sales(6) were up 6.0%, reflecting strong performance in Asia. Full-Year 2018 sales growth from new products and Emerging markets more than offset impact of U.S. LoEs Net sales in 2018 were €34,463 million, down 1.7% on a reported basis and grew 2.5% at CER (up 0.6% at CER/CS(4)). Sanofi Genzyme grew 30.8% (+14.2% at CER/CS(4)) to €7,226 million. Vaccines sales increased 2.4% to €5,118 million while CHC sales were up 3.0% to €4,660 million. DCV(5) GBU sales declined 13.8% to €4,511 million. Emerging Markets sales were up 7.5%, supported by strong performance in China (up 12.7%). Sanofi delivers 2018 business EPS at the high end of its guidance range Q4 2018 business EPS(1) up 4.7% at CER to €1.10. Full-Year 2018 business EPS of €5.47 up 5.1% at CER and IFRS EPS of €3.45 (down 48.5%(2)). Board proposes dividend of €3.07, the 25th consecutive increase in dividend. Key achievements in sustaining innovation in R&D Isatuximab met primary endpoint of ICARIA phase 3 study in Relapsed/Refractory Multiple Myeloma. BIVV001 demonstrated sustained high factor levels at once-weekly dosing with data presented at ASH. FDA Priority Review granted for Dupixent® in adolescents with moderate-to-severe atopic dermatitis. R&D strategy evolves towards prioritization of Specialty Care and Vaccines, leveraging technology platforms and data science. 2019 financial outlook Sanofi expects 2019 business EPS(1) to grow between 3% and 5%(7) at CER, barring unforeseen major adverse events. Applying average January 2019 exchange rates, the positive currency impact on 2019 business EPS is estimated to be between 1% to 2%. |
| Sanofi Chief Executive Officer, Olivier Brandicourt, commented: "In the fourth quarter, we continued the momentum of the previous quarter and we delivered 5% full-year business EPS growth, at the high end of our guidance. In 2018, we executed on important launches including Dupixent®, Libtayo® and Cablivi®, as the headwinds from our U.S. LoEs began to moderate. Additionally, the acquisitions of Bioverativ and Ablynx provided the foundation to build a leading Rare Blood Disorder franchise and to enhance our biologic discovery capabilities. As we enter 2019, our focus remains on delivering our business priorities and transforming Sanofi to address the evolving business dynamics facing our industry." |
(1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (see Appendix 10 for definitions). The consolidated income statement for Q4 2018 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) Excluding Animal Health gain on disposal, full-year IFRS net income was up 14.5% and full-year IFRS EPS was up 15.3%; (3) Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 10); (4) Constant Structure: Adjusted for Bioverativ acquisition and divestment of European Generics business; (5) DCV: Diabetes and Cardiovascular; (6) See definition page 8; (7) 2018 business EPS was €5.47.
| Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - Media Relations: (+) 33 1 53 77 46 46 - E-mail: MR@sanofi.com Website: www.sanofi.com Mobile app: SANOFI IR available on the App Store and Google Play |
2018 fourth-quarter and full-year Sanofi sales
| Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER(8). |
In the fourth quarter of 2018, Company sales were €8,997 million, up 3.5% on a reported basis. Exchange rate movements had a negative effect of 0.4 percentage points mainly driven by the movement of the Turkish Lira, Brazilian Real and Argentine Peso. At CER, Company sales increased 3.9%.
Full-year Company sales reached €34,463 million, down 1.7% on a reported basis. Exchange rate movements had an unfavorable effect of 4.2 percentage points. At CER, Company sales were up 2.5%.
Global Business Units
The table below presents sales by Global Business Unit (GBU). Please note that Emerging Markets sales for Specialty Care and Diabetes and Cardiovascular are included in the General Medicines and Emerging Markets GBU.
| Net Sales by GBU (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER | ||
| Sanofi Genzyme (Specialty Care)(a) | 2,054 | +37.4%(c) | 7,226 | +30.8%(d) | ||
| Diabetes and Cardiovascular(a) | 1,170 | -11.3% | 4,511 | -13.8% | ||
| General Medicines & Emerging Markets(b) | 3,052 | -6.6%(e) | 12,948 | -2.8%(f) | ||
| Total Pharmaceuticals | 6,276 | +3.0% | 24,685 | +2.4% | ||
| Consumer Healthcare (CHC) | 1,194 | +1.9% | 4,660 | +3.0% | ||
| Sanofi Pasteur (Vaccines) | 1,527 | +9.7% | 5,118 | +2.4% | ||
| Total net sales | 8,997 | +3.9% | 34,463 | +2.5% | ||
(a) Does not include Emerging Markets sales - see definition page 8; (b) Includes Emerging Markets sales for Diabetes & Cardiovascular and Specialty Care; (c)+16.1% at CS; (d)+14.2% at CS; (e) -1.8% at CS; (f)-1.6% at CS
Global Franchises
The tables below present fourth-quarter and 2018 sales by global franchise, including Emerging Markets sales, to facilitate comparisons. Appendix 1 provides a reconciliation of sales by GBU and franchise.
| Net sales by Franchise (€ million) | Q4 2018 | Change at CER | Developed Markets | Change at CER | Emerging Markets | Change at CER |
| Specialty Care | 2,328 | +35.2% | 2,054 | +37.4% | 274 | +22.4% |
| Diabetes and Cardiovascular | 1,552 | -7.1% | 1,170 | -11.3% | 382 | +7.9% |
| Established Rx Products | 2,126 | -6.8% | 1,242 | -13.0% | 884 | +2.9% |
| Consumer Healthcare (CHC) | 1,194 | +1.9% | 789 | -0.4% | 405 | +6.4% |
| Generics | 270 | -33.8%* | 97 | -61.4%** | 173 | +3.8% |
| Vaccines | 1,527 | +9.7% | 1,054 | +13.3% | 473 | +2.5% |
| Total net sales | 8,997 | +3.9% | 6,406 | +3.0% | 2,591 | +6.0% |
* +6.7% at CS
**+12.9% at CS
| Net sales by Franchise (€ million) | 2018 | Change at CER | Developed Markets | Change at CER | Emerging Markets | Change at CER |
| Specialty Care | 8,269 | +29.0% | 7,226 | +30.8% | 1,043 | +18.7% |
| Diabetes and Cardiovascular | 6,083 | -7.9% | 4,511 | -13.8% | 1,572 | +13.1% |
| Established Rx Products | 8,843 | -6.1% | 5,090 | -14.1% | 3,753 | +6.6% |
| Consumer Healthcare (CHC) | 4,660 | +3.0% | 3,072 | -0.1% | 1,588 | +8.9% |
| Generics | 1,490 | -9.8%* | 805 | -19.4%** | 685 | +3.0% |
| Vaccines | 5,118 | +2.4% | 3,647 | +4.5% | 1,471 | -2.3% |
| Total net sales | 34,463 | +2.5% | 24,351 | +0.5% | 10,112 | +7.5% |
* -0.6% at CS
**-3.8% at CS
(8) See Appendix 10 for definitions of financial indicators.
Pharmaceuticals
Fourth-quarter Pharmaceutical sales were up 3.0% to €6,276 million mainly driven by the Immunology and Rare Blood Disorder franchises which were partially offset by Diabetes, Established Rx Products and the disposal of the European generics business. Full-year sales for Pharmaceuticals increased 2.4% to €24,685 million.
Rare Disease franchise
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Myozyme® / Lumizyme® | 226 | +10.7% | 840 | +10.8% |
| Fabrazyme® | 206 | +14.4% | 755 | +9.8% |
| Cerezyme® | 190 | +9.3% | 711 | +6.4% |
| Aldurazyme® | 54 | +16.7% | 206 | +6.7% |
| Cerdelga® | 44 | +33.3% | 159 | +31.0% |
| Others Rare Disease | 74 | -6.5% | 287 | -5.4% |
| Total Rare Disease | 794 | +10.9% | 2,958 | +8.3% |
In the fourth quarter, Rare Disease delivered a solid performance with sales up 10.9% to €794 million, driven by Gaucher, Pompe and Fabry therapies. In the U.S. and Europe, fourth-quarter Rare Disease sales grew 8.5% (to €292 million) and 3.1% (to €262 million), respectively, while Emerging Markets sales were up 32.6% to €150 million. Full-year Rare Disease sales increased 8.3% to €2,958 million.
Fourth-quarter Gaucher (Cerezyme® and Cerdelga®) sales were up 13.0% to €234 million, supported by the increasing penetration of Cerdelga® in Europe and the sustained growth of Cerezyme® in Emerging Markets. Fourth-quarter Cerdelga® sales increased 33.3% to €44 million. Full-year Gaucher sales were €870 million, up 10.0%.
Fourth-quarter Pompe (Myozyme®/Lumizyme®) sales grew 10.7% to €226 million, supported by positive trends in naïve patient accruals. Fourth-quarter Myozyme®/Lumizyme® sales increased 18.8% to €79 million in the U.S. and 1.1% to €96 million in Europe, respectively. Full-year Myozyme®/Lumizyme® sales increased 10.8% to €840 million.
Fourth-quarter Fabry (Fabrazyme®) sales grew 14.4% to €206 million. Fourth-quarter sales in the U.S. and Europe increased 9.9% (to €104 million) and 4.8% (to €45 million), respectively. Full-year Fabrazyme® sales were up 9.8% to €755 million.
Multiple Sclerosis franchise
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Aubagio® | 446 | +12.6% | 1,647 | +9.3% |
| Lemtrada® | 96 | -14.3% | 402 | -11.6% |
| Total Multiple Sclerosis | 542 | +6.6% | 2,049 | +4.4% |
Fourth-quarter Multiple Sclerosis (MS) sales were up 6.6% to €542 million, as double-digit Aubagio® sales growth was partially offset by the decline in Lemtrada® sales. Full-year MS sales increased 4.4% to €2,049 million.
Fourth-quarter Aubagio® sales increased 12.6% to €446 million, driven by the U.S. (up 13.5% to €311 million) and Europe (up 12.5% to €108 million). Full-year Aubagio® sales increased 9.3% to €1,647 million.
In the fourth quarter, Lemtrada® sales decreased 14.3% to €96 million due to lower U.S. sales (down 19.6% to €45 million) and European sales (down 11.9% to €37 million), reflecting increased competition. Full-year Lemtrada® sales decreased 11.6% to €402 million.
Immunology franchise
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Dupixent® | 280 | +130.5% | 788 | +268.0% |
| Kevzara® | 31 | +275.0% | 83 | +663.6% |
| Total Immunology | 311 | +139.7% | 871 | +287.0% |
Dupixent® (collaboration with Regeneron) for the treatment of moderate-to-severe atopic dermatitis in adults and moderate-to-severe adolescent and adult asthma generated sales of €280 million in the fourth quarter compared to €118 million in the fourth quarter of 2017. In the U.S., Dupixent® sales reached €225 million in the fourth quarter (up 87.9%). Demand for the product remains strong and total prescriptions IQVIA increased 25% sequentially in the fourth quarter, bolstered by the branded DTC campaign and the recent U.S. launch in asthma. Fourth-quarter sales in Europe were €29 million. Full-year Dupixent® sales were €788 million compared to €219 million in the same period of 2017. By the end of 2018, Dupixent® had been launched in 17 countries.
Kevzara® (collaboration with Regeneron) for rheumatoid arthritis generated sales of €31 million in the fourth quarter, of which €23 million was in the U.S. reflecting improved commercial coverage. Kevzara® was launched in 14 countries in Europe in 2018 (included France in the fourth quarter). Full-year Kevzara® sales were €83 million.
Rare Blood Disorder franchise
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Eloctate® | 196 | - | 608 | - |
| Alprolix® | 95 | - | 285 | - |
| Cablivi® | 3 | - | 4 | - |
| Total Rare Blood Disorder | 294 | - | 897 | - |
Bioverativ was consolidated in Sanofi's Financial Statements from March 9, 2018. Fourth-quarter sales of the Rare Blood Disorder franchise were €294 million (up 5.7% on a pro forma basis(9)), including non-U.S. sales of €58 million with Japan as the primary contributor. Full-year consolidated sales of the Rare Blood Disorder franchise were €897 million, up 12.5% on a pro forma basis(9).
Eloctate®, a recombinant antihemophilic Factor VIII, indicated for the treatment of hemophilia A, generated sales of
€196 million in the fourth quarter, up 4.3% on a pro forma basis(10). The performance in the U.S., Japan and Australia was partially offset by a decline in sales in Canada following the previously announced tender loss. The competitive dynamics in the U.S. resulted in a deceleration in growth compared with the previous quarter. Full-year consolidated Eloctate® sales were €608 million, up 15.0% on a pro forma basis(10).
Alprolix®, a recombinant coagulation Factor IX, indicated for the treatment of hemophilia B, generated sales of €95 million in the fourth quarter, up 5.3% on a pro forma basis(10). Full-year consolidated Alprolix® sales were €285 million, up 6.6% on a pro forma basis(10).
Cablivi® (caplacizumab) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), received EU approval in September and was launched in its first market, Germany, in October. Sales in the fourth quarter were €3 million.
Oncology franchise
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Jevtana® | 114 | +14.1% | 422 | +13.0% |
| Thymoglobulin® | 78 | +9.9% | 297 | +7.2% |
| Mozobil® | 47 | +15.0% | 171 | +8.6% |
| Eloxatin® | 43 | 0.0% | 182 | +5.0% |
| Taxotere® | 38 | -2.5% | 166 | -0.6% |
| Zaltrap® | 23 | +14.3% | 91 | +27.0% |
| Others | 44 | 0.0% | 165 | -32.1% |
| Total Oncology | 387 | +8.1% | 1,494 | +2.1% |
(9) Growth comparing fourth-quarter 2018 sales versus fourth-quarter 2017 sales, and full 2018 sales versus full 2017 sales at CER. Excluding the Sobi contract manufacturing sales and including Cablivi® sales in 2018. Unaudited data. (10) Growth comparing fourth-quarter 2018 sales versus fourth-quarter 2017 sales, and full 2018 sales versus full 2017 sales at CER. Excluding the Sobi contract manufacturing sales. Unaudited data.
Fourth-quarter Oncology sales increased 8.1% to €387 million. Consistent with the Company's portfolio prioritization efforts, Sanofi sold Leukine® on January 31, 2018. Excluding Leukine®, Oncology fourth-quarter sales were up 10.2%. Full-year Oncology sales were up 2.1% to €1,494 million and up 6.3% excluding Leukine®.
Jevtana® sales were up 14.1% to €114 million in the fourth quarter supported by the performance in the U.S. (up 20.0% to €50 million). Full-year Jevtana® sales increased 13.0% to €422 million. In the fourth quarter and full year, Thymoglobulin® sales increased 9.9% (to €78 million) and 7.2% (to €297 million), respectively.
In September, Libtayo® (cemiplimab-rwlc, collaboration with Regeneron) was approved in the U.S. for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo® is the only treatment for advanced CSCC approved by the FDA. U.S. Libtayo® sales were $15 million and were consolidated by Regeneron.
Diabetes franchise
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Lantus® | 866 | -19.7% | 3,565 | -19.0% |
| Toujeo® | 211 | -2.3% | 840 | +7.2% |
| Total glargine | 1,077 | -16.8% | 4,405 | -15.1% |
| Apidra® | 89 | -6.2% | 357 | +0.3% |
| Amaryl® | 77 | -1.3% | 335 | +4.8% |
| Insuman® | 23 | -14.8% | 91 | -12.0% |
| Admelog® | 57 | - | 93 | - |
| Soliqua® | 27 | +188.9% | 73 | +188.5% |
| Total Diabetes | 1,375 | -10.5% | 5,472 | -10.4% |
In the fourth quarter, global Diabetes sales decreased 10.5% to €1,375 million, due to lower glargine (Lantus® and Toujeo®) sales in the U.S. Fourth-quarter U.S. Diabetes sales were down 26.3% to €555 million, reflecting the previously announced changes in coverage of the Part D business and a continued decline in average U.S. glargine net prices. Fourth-quarter sales in Emerging Markets increased 7.7% to €376 million. Fourth-quarter sales in Europe decreased 0.6% to €320 million, supported by Toujeo® growth. Full-year global Diabetes sales decreased 10.4% to €5,472 million. This in turn resulted in a CAGR sales decline for the global Diabetes franchise over 2015-2018 of 7.4% at CER, in line with the guidance.
Fourth-quarter glargine (Lantus® and Toujeo®) sales decreased 16.8% to €1,077 million. U.S. glargine sales were down 35.7% to €460 million, reflecting the aforementioned changes in coverage in Part D and a continued decline in average U.S. glargine net prices. In Europe, glargine sales were stable ato €245 million reflecting strong Toujeo® performance. Full-year glargine sales decreased 15.1% to €4,405 million. In 2019, Sanofi expects a further net pricing decline for its glargine products in the U.S. as a result of higher rebates needed to maintain broad payer coverage and the increased Part D coverage gap impact.
In the fourth quarter, Lantus® sales were €866 million, down 19.7%. In the U.S., Lantus® sales decreased 37.0% to €379 million, mainly reflecting lower average net price and changes in coverage in Part D. In Europe, fourth-quarter Lantus® sales were €168 million, down 8.2% due to biosimilar glargine competition and patients switching to Toujeo®. In Emerging Markets, fourth-quarter Lantus® sales were up 7.7% to €242 million. Full-year Lantus® sales decreased 19.0% to €3,565 million.
Fourth-quarter Toujeo® sales were €211 million, down 2.3%. In the U.S., fourth-quarter Toujeo® sales were €81 million, down 29.1%. In Europe and Emerging Markets, fourth-quarter Toujeo® sales were €77 million (up 23.8%) and €31 million (up 32.0%), respectively. Full-year Toujeo® sales increased 7.2% to €840 million.
Fourth-quarter Apidra® sales decreased 6.2% to €89 million. Lower sales in the U.S. (down 36.0% to €17 million) offset growth in Emerging Markets (up 10.7% to €29 million). Full-year Apidra® sales increased 0.3% to €357 million.
Amaryl® sales were €77 million, down 1.3% in the fourth quarter, of which €66 million were generated in Emerging Markets (up 1.5%). Full-year Amaryl® sales were up 4.8% at €335 million.
Admelog® (insulin lispro injection) 100 Units/mL, which was launched in the U.S. in April, generated sales of €57 million in the fourth quarter mainly due to access in Managed Medicaid. Full-year Admelog® sales were €93 million.
Fourth-quarter and full-year Soliqua® 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) and Suliqua(TM) sales were €27 million and €73 million, respectively.
Cardiovascular franchise
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Praluent® | 82 | +50.9% | 261 | +56.1% |
| Multaq® | 95 | +20.8% | 350 | +7.1% |
| Total cardiovascular franchise | 177 | +33.1% | 611 | +23.5% |
Fourth-quarter Praluent® (collaboration with Regeneron) sales increased 50.9% to €82 million. U.S. sales of €52 million (up 45.7%) benefited from ESI coverage exclusivity which began in the third quarter. In Europe, sales were €23 million (up 53.3%). Full-year Praluent® sales increased 56.1% to €261 million. In 2019, Sanofi expects higher U.S. rebates to impact Praluent® sales.
Fourth-quarter and full-year Multaq® sales were up 20.8% (to €95 million) and 7.1% (to €350 million), respectively.
Established Rx Products
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Lovenox® | 346 | -9.0% | 1,465 | -3.0% |
| Plavix® | 328 | -4.9% | 1,440 | +1.2% |
| Aprovel®/Avapro® | 151 | -2.5% | 652 | -1.7% |
| Renvela®/Renagel® | 96 | -39.4% | 411 | -46.7% |
| Synvisc® /Synvisc-One® | 81 | -7.0% | 313 | -15.0% |
| Myslee®/Ambien®/Stilnox® | 59 | -1.7% | 231 | -6.9% |
| Allegra® | 26 | -21.9% | 124 | -17.7% |
| Other | 1,039 | -2.5% | 4,207 | -1.8% |
| Total Established Rx Products | 2,126 | -6.8% | 8,843 | -6.1% |
In the fourth quarter, Established Rx Products sales decreased 6.8% to €2,126 million, reflecting lower U.S. sales of Renvela®/Renagel® (sevelamer) due to generic competition, together with lower sales of Lovenox® in Europe and Plavix® in Japan. Full-year Established Rx Products sales decreased 6.1% to €8,843 million.
Fourth quarter Lovenox® sales decreased 9.0% to €346 million, reflecting biosimilar competition in the UK, Poland, Germany, Italy and France. Sales in Europe were down 13.9% to €199 million impacted mainly by price erosion in France and Germany triggered by biosimilar launches. In Emerging Markets, Lovenox® sales grew 3.3% to €117 million. Full-year Lovenox® sales were down 3.0% to €1,465 million
In the fourth quarter, Plavix® sales were down 4.9% to €328 million. The decline was mainly driven by generic penetration in Japan (sales down 31.5% to €38 million) and procurement timing in the Middle East. Plavix® sales continued to grow in China. Sales of the product decreased in the rest of Emerging Markets and increased 2.9% in Europe. Full-year Plavix® sales were up 1.2% to €1,440 million.
Fourth-quarter Aprovel®/Avapro® sales decreased 2.5% to €151 million due to loss of exclusivity in Japan in December 2017. In Emerging Markets, performance continued to be strong with sales up 8.6% to €112 million. Full-year Aprovel®/Avapro® sales decreased 1.7% to €652 million.
Fourth-quarter Renvela®/Renagel® (sevelamer) sales decreased 39.4% to €96 million due to generic competition in the U.S. (down 53.0% to €57 million). Full-year Renvela®/Renagel® sales decreased 46.7% to €411 million.
Generics
In the fourth quarter, Generics sales decreased 33.8% to €270 million, reflecting the divestment of the European generics business Zentiva at the end of the third quarter. This divestiture was consistent with Sanofi's strategy to simplify and reshape the company. At CS, fourth quarter Generic sales increased 6.7%. Emerging Markets Generics sales increased 3.8% to €173 million. Full-year Generics sales decreased 9.8% to €1,490 million and decreased 0.6% at CS.
Consumer Healthcare
CHC sales by geography and category are provided in Appendix 1.
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Allergy Cough & Cold | 268 | -6.3% | 1,124 | -1.7% |
| of which Allegra® | 80 | -3.6% | 396 | +1.2% |
| of which Mucosolvan® | 30 | -14.3% | 110 | +1.8% |
| of which Xyzal® | 10 | +42.9% | 41 | -32.3% |
| Pain | 336 | +4.6% | 1,254 | +6.7% |
| of which Doliprane® | 98 | +3.2% | 333 | +4.0% |
| of which Buscopan® | 49 | 0.0% | 194 | +16.0% |
| Digestive | 256 | +4.4% | 986 | +8.7% |
| of which Dulcolax® | 55 | 0.0% | 216 | +7.1% |
| of which Enterogermina® | 47 | +14.3% | 183 | +16.1% |
| of which Essentiale® | 48 | +4.1% | 177 | +8.7% |
| of which Zantac® | 34 | +13.8% | 127 | +13.7% |
| Nutritionals | 174 | +9.1% | 675 | +4.7% |
| Other | 160 | 0.0% | 621 | -5.2% |
| of which Gold Bond® | 67 | +16.1% | 211 | +9.5% |
| Total Consumer Healthcare | 1,194 | +1.9% | 4,660 | +3.0% |
In the fourth quarter, Consumer Healthcare (CHC) sales increased 1.9% to €1,194 million, driven by Emerging Markets and the U.S. Full-year CHC sales increased 3.0% to €4,660 million.
In Europe, fourth-quarter CHC sales were down 3.6% to €368 million. Lower sales in the Allergy Cough & Cold category (down 13.3%) resulted from a weak season coupled with a strong base for comparison in the fourth quarter of 2017, which featured an unusual spike in demand. Full-year CHC sales in Europe decreased 0.2% to €1,403 million.
In the U.S., fourth-quarter CHC sales increased 6.0% to €274 million, supported by the Digestive category (up 10.9%) and Gold Bond performance. Full-year U.S. CHC sales decreased 1.1% to €1,066 million.
In Emerging Markets, fourth-quarter CHC sales increased 6.4% to €405 million, mainly driven by a solid demand in Brazil (mainly Pain category). Full-year Emerging Markets CHC sales increased 8.9% to €1,588 million.
Vaccines
| Net sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| Influenza vaccines (incl. Vaxigrip®, Fluzone HD®, Fluzone®, Flublok®) | 596 | +17.1% | 1,708 | +7.2% |
| Polio/Pertussis/Hib vaccines (incl. Hexaxim® / Hexyon®, Pentacel®, Pentaxim® and Imovax®) | 504 | +3.0% | 1,749 | -0.7% |
| Meningitis/Pneumo vaccines (incl. Menactra®) | 131 | +59.3% | 609 | +0.6% |
| Adult Booster vaccines (incl. Adacel ®) | 135 | -2.9% | 470 | +1.3% |
| Travel and other endemic vaccines | 130 | -18.8% | 488 | +1.8% |
| Other vaccines | 31 | +158.3% | 94 | +3.2% |
| Total Vaccines | 1,527 | +9.7% | 5,118 | +2.4% |
Fourth-quarter Vaccines sales were up 9.7% driven by the performance in the U.S. (up 10.4%) and Europe (up 21.9%). In Emerging Markets, fourth-quarter Vaccines sales increased 2.5%. Fourth-quarter performance was consistent with Sanofi's expectation that sales of the Vaccines GBU would grow mid to high-single digits in the second half of 2018. Full-year Vaccines sales increased 2.4% to €5,118 million.
Fourth-quarter Influenza vaccines sales were up 17.1% to €596 million, reflecting slightly greater weighting of shipments in the fourth quarter versus the prior year as well as Sanofi Pasteur's influenza differentiation strategy which included the successful launch of Flubok® in the U.S. and the strong performance of Vaxigrip® QIV in Europe. Full-year Influenza vaccines sales increased 7.2% to €1,708 million.
In the fourth quarter, Polio/Pertussis/Hib (PPH) vaccines sales were up 3.0% to €504 million, driven by higher Hexaxim sales in Emerging Markets. In China, Pentaxim® supply returned to normal. In the U.S., PPH vaccines sales decreased 9.2% to €102 million reflecting lower sales of Polio and Hib vaccines. Full-year Polio/Pertussis/Hib vaccines sales were down 0.7% to €1,749 million.
Fourth-quarter Menactra® sales increased 63.3% to €130 million, driven by sales in the U.S. and Middle-East. In the U.S., fourth-quarter Menactra® sales were €80 million (up 45.3%) reflecting timing differences in CDC and wholesaler buying patterns. Full-year Menactra® sales were up 4.5% to €608 million.
Fourth-quarter and full-year Adult Booster vaccines sales decreased 2.9% (to €135 million) and increased 1.3% (to €470 million), respectively.
Fourth-quarter Travel and other endemic vaccines sales were €130 million, down 18.8% reflecting lower Rabies and Typhoid vaccines sales. Full-year Travel and other endemic vaccines sales were up 1.8% to €488 million.
Company sales by geographic region
| Sanofi sales (€ million) | Q4 2018 | Change at CER | 2018 | Change at CER |
| United States | 3,195 | +8.7% | 11,540 | +0.7% |
| Emerging Markets(a) | 2,591 | +6.0% | 10,112 | +7.5% |
| of which Asia | 941 | +8.4% | 3,962 | +9.3% |
| of which Latin America | 710 | +2.6% | 2,612 | +8.1% |
| of which Africa, Middle East | 601 | +5.2% | 2,232 | +1.1% |
| of which Eurasia(b) | 288 | +3.3% | 1,152 | +10.1% |
| Europe(c) | 2,342 | -4.8% | 9,434 | -0.6% |
| Rest of the World(d) | 869 | +6.7% | 3,377 | +2.7% |
| of which Japan | 423 | -1.4% | 1,710 | -2.0% |
| Total Sanofi sales | 8,997 | +3.9% | 34,463 | +2.5% |
- World excluding U.S., Canada, Western & Eastern Europe (except Eurasia), Japan, South Korea, Australia, New Zealand and Puerto Rico
- Russia, Ukraine, Georgia, Belarus, Armenia and Turkey
- Western Europe + Eastern Europe except Eurasia
- Japan, South Korea, Canada, Australia, New Zealand, Puerto Rico
Fourth-quarter sales in the U.S. were up 8.7% to €3,195 million. This mainly reflected the strong performances of Dupixent® and Aubagio®, together with the consolidation of Eloctate® and Alprolix® sales, which were partly offset by lower sales of the Diabetes franchise (down 26.3%) and of sevelamer. In the U.S., full-year sales increased 0.7% to €11,540 million.
Fourth-quarter sales in Emerging Markets increased 6.0% to €2,591 million, mainly driven by Rare Diseases (up 32.6%), Diabetes (up 7.7%) and CHC (up 6.4%). In Asia, sales were up 8.4% to €941 million in the fourth quarter, sustained by the performance in China (up 8.3% to €566 million). In Latin America, fourth-quarter sales increased 2.6% to €710 million. Fourth-quarter sales in Brazil were up 10.0% to €254 million. In Africa and the Middle East region, fourth-quarter sales were €601 million, up 5.2%. Fourth-quarter sales in the Eurasia region increased 3.3% to €288 million, driven by the growth in Turkey which was partially offset by lower sales in Russia (€153 million, down 4.0%). Full-year sales in Emerging Markets increased 7.5% to €10,112 million. In 2018, sales in China, Brazil and Russia were €2,464 million (up 12.7%), €1,023 million (up 7.0%) and €605 million (up 4.6%), respectively.
Fourth-quarter sales in Europe were €2,342 million, down 4.8% due to the divestment of the European Generics business. At CS, fourth-quarter sales were up 2.0% driven by Vaccines (up 21.9%) and the roll-out of Dupixent® which offset lower sales in Established Rx Products (down 6.8%). In Europe, full-year sales decreased 0.6% to €9,434 million and increased 1.1% at CS.
Sales in Japan decreased 1.4% to €423 million in the fourth quarter. The consolidation of Rare Blood Disorder sales was more than offset by the impact of Plavix® and Aprovel® generic competition and lower Vaccines sales. In Japan, full-year sales decreased 2.0% to €1,710 million.
R&D update
| Consult Appendix 6 for full overview of Sanofi's R&D pipeline |
R&D strategy
Sanofi is today providing an update on the evolution of its R&D strategy. Consistent with its ambition to be an industry innovation leader, Sanofi has increased its R&D focus on Specialty Care therapy areas (Oncology, Immunology, Rare Disease and Rare Blood Disorder) while maintaining its commitment to Vaccines. Since 2017, the number of R&D programs in these areas has increased significantly, and they now represent over 90% of Sanofi's clinical portfolio. This change reflects advances in the Company's R&D capabilities and understanding of human biology.
In support of this strategy, Sanofi recently carried out a rigorous pipeline prioritization review to accelerate investment behind its most promising programs and to discontinue those with a less attractive expected return profile. As a result, the Company is accelerating the development of 17 programs, including 8 in Oncology. Thirteen development projects and 25 research projects are being discontinued to enhance the company's focus on delivering first and best in class medicines. Overall, Sanofi could potentially submit 9 new medicines and 25 additional indications to regulatory authorities over 2019 to 2022.
Through the development of its own expertise and the establishment of partnerships with industry pioneers, Sanofi has access to a broad range of therapeutic modalities that enable a more customized, science-driven approach to targeting disease. This includes development of next-generation biologics, such as multi-specific antibodies and Nanobodies, which provide new opportunities relative to traditional monoclonal antibodies in areas such as oncology and immunology, as well as gene therapies. The Company is also employing data science and machine learning across the R&D organization to generate higher quality data, accelerate development and regulatory submissions, and reduce costs. Sanofi expects to maintain an annual R&D budget of approximately €6 billion through 2021.
Regulatory update
Regulatory updates since October 31, 2018 include the following:
- In February, the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Praluent® (collaboration with Regeneron) in European Union to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease.
- In December, the FDA approved the hexavalent vaccine, Vaxelis(TM), for use in children from 6 weeks through 4 years of age. Vaxelis(TM) was developed as part of a joint partnership between Sanofi and Merck in the U.S. and Canada. Commercial supply will not be available in the U.S. prior to 2020.
- In December, Dupixent® ( collaboration with Regeneron) was submitted to the FDA for the treatment of adults with inadequately-controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
- In December, the European Commission granted marketing authorization for Dengvaxia® to prevent dengue disease in individuals 9-45 years of age with a documented prior dengue infection and who are living in endemic areas.
- In November, the CHMP recommended approval in European Union of fexinidazole the first all-oral treatment for sleeping sickness.
- In November, the FDA accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease is inadequately controlled with topical therapies or for whom topical treatment is medically inadvisable. The target action data for the FDA decision is March 11, 2019.
At the beginning of February 2019, the R&D pipeline contained 81 projects including 33 new molecular entities in clinical development. 35 projects are in phase 3 or have been submitted to the regulatory authorities for approval.
Portfolio update
Phase 3:
- In February, Sanofi announced that Isatuximab phase 3 trial (ICARIA study) met primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
- In January, the New England Journal of Medicine (NEJM) published positive results of the Phase 3 trial of Cablivi® (caplacizumab) in adults with acquired thrombotic thrombocytopenic purpura (aTTP).
- In November, new analyses on mortality from the ODYSSEY OUTCOMES trial evaluating Praluent® were presented at the American Heart Association (AHA) Scientific Sessions. In November, the New England Journal of Medicine (NEJM) also published detailed results of this trial.
- Shan 6, a pediatric hexavalent vaccine, entered phase 3.
Phase 2:
- A phase 2 study evaluating the combination of isatuximab (anti-CD38 mAb) and cemiplimab (collaboration with Regeneron) in lymphoma was intitiated.
- A phase 2 study evaluating the combination of isatuximab and atezolizumab (PD-L1 inhibitor mAb) in solid tumors was initiated.
- A phase 2 study evaluating SAR440340 (an anti-IL33 mAb, collaboration with Regeneron) in atopic dermatitis was initiated.
- Positive primary analysis of the Phase 2b trial demonstrated the safety and efficacy of SP0232/MEDI8897 (anti RSV mAb - Respiratory Syncytial Virus, collaboration with Medimmune).
- Several projects in phase 2 were stopped:
- GZ389988, a TRKA antagonist, in osteo arthritis;
- ALX0171, an anti RSV nanobody (from Ablynx) for Respiratory Syncitial Virus;
- SAR425899, a GLP-1 / GCGR agonist, in obesity in type 2 diabetes patients;
- SAR407899, a rho kinase inhibitor, for microvascular angina;
Phase 1:
- SAR408701, an anti-CEACAM5, achieved positive proof of concept in a subgroup of lung cancer patients. A broad development program is expected to start by the end of 2019.
- BIVV001, a recombinant Factor VIII for Hemophilia A, achieved positive proof of concept with demonstration of sustained high factor levels at once-weekly dosing.
- SAR441000, a cytokine mRNA (collaboration withBioNTech AG) entered phase 1 in the treatment of melanoma.
- SAR443060/DNL747 (collaboration with Denali), an oral brain-penetrant small molecule (RIPK1 inhibitor), entered phase 1 clinical study in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease.
- BIVV003, a Zinc Finger Nuclease (ZFN) gene editing technology issued from Bioverativ entered phase 1 in the treatment of sickle cell disease.
- SAR441344, an anti-CD40L mAb (license from ImmuNext), entered phase 1 in the treatment of multiple sclerosis.
- A next generation Pneumococcal Conjugate Vaccine (PCV) entered phase 1.
- Several projects in phase 1 were stopped:
- SAR439794, a TLR4 agonist immunomodulatory evaluated in peanut allergy;
- SAR247799, a S1P1 agonist evaluated in cardiovascular area;
- SAR438335, a GLP-1/GIP agonist in Type 2 diabetes;
- SAR228810, an anti protofibrillar AB mAb for Alzheimer disease;
- UshStat®, a myosin 7A gene therapy for Usher Syndrome 1B, will be discontinued contigent upon identification of out-licensing partner.
Collaborations
In January 2019, Sanofi and Regeneron announced a restructuring of their global Immuno-Oncology Discovery and Development Agreement for new IO cancer treatments. The 2015 agreement was scheduled to end in approximately mid-2020. This revision provides for ongoing collaborative development of two clinical-stage bispecific antibody programs (BCMAxCD3 and MUC16xCD3 bispecific). It also provides Sanofi with increased flexibility to advance its early-stage IO pipeline independently while Regeneron retains all rights to its other IO discovery and development programs.
In January 2019, BioNTech announced that it has extended its research collaboration with Sanofi initiated in late 2015 in the field of mRNA cancer immunotherapy.
In January 2019, MyoKardia, Inc. announced that it regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration has not been extended beyond the initial research term, which ended on December 31, 2018. As a result, MyoKardia now has regained global rights to all programs in its portfolio, including mavacamten (a Myosin inhibitor evaluated in obstructive and non-obstructive hypertrophic cardiomyopathy) and MYK-491 (a Myosin activator evaluated in dilated cardiomyopathy) and the license and collaboration will conclude in its entirety effective April 1, 2019.
In December sanofi and Medicines for Malaria Ventures (MMV) agreed to transfer the operational responsibility for the development of Ferroquine/OZ439, to MMV in such a way that MMV would assume leadership while sanofi remains the sponsor of the studies, fulfilling drug supply, regulatory and legal obligations. Ferroquine/OZ439 is a first in class combination for malaria previously developed in collaboration with MMV.
In November, Sanofi announced that it plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases.
2018 Fourth-quarter and full-year financial results(11)
Business Net Income(11)
In the fourth quarter of 2018, Sanofi generated net sales of €8,997 million, an increase of 3.5% (up 3.9% at CER). Full-year sales were €34,463 million, down 1.7% on a reported basis (up 2.5% at CER).
Fourth-quarter other revenues increased 13.4% (up 10.3% at CER) to €329 million, reflecting the VaxServe sales contribution of non-Sanofi products (€262 million, up 13.9% at CER) and the royalties received from Swedish Orphan Biovitrum AB. Full-year other revenues increased 5.7% (up 9.3% at CER) to €1,214 million of which €959 million were generated by VaxServe (up 15.6% at CER).
Fourth-quarter Gross Profit increased 5.2% to €6,188 million (up 5.2% at CER). The gross margin ratio was 68.8% (68.6% at CER) versus 67.7% in the fourth quarter of 2017. The positive mix impact of Specialty Care as well as the contribution from Bioverativ and Vaccines (impacted by Dengvaxia® in the fourth quarter of 2017) more than offset the negative impacts from U.S. Diabetes net price evolution and sevelamer generic competition. In the fourth quarter of 2018, the gross margin ratio of segments was 72.1% for Pharmaceuticals (down 0.2 percentage points), 66.0% for CHC (up 1.6 percentage points) and 60.4% for Vaccines (up 4.9 percentage points). Full-year Gross Profit decreased 1.7% to €24,356 million (up 2.5% at CER). In 2018, the gross margin ratio increased 0.1 percentage point to 70.7% (70.6% at CER) versus 2017. In 2019, Sanofi expects its gross margin ratio to be around 70% at CER.
Research and Development (R&D) expenses increased 14.6% to €1,678 million in the fourth quarter of 2018. At CER, R&D expenses increased 13.5%, mainly reflecting the acquisitions of Bioverativ and Ablynx together with the investments in the immuno-oncology and diabetes programs. Excluding the impact of acquisitions, R&D expenses would have risen by 6.7% in the fourth quarter of 2018. Full-year R&D expenses increased 7.7% to €5,894 million (up 10.3% at CER).
Fourth-quarter selling general and administrative expenses (SG&A) increased 0.8% to €2,721 million. At CER, SG&A expenses were up 1.1% mainly reflecting consolidation of Bioverativ and Ablynx. Additional marketing investments in new launches were offset by lower Diabetes expenses in the U.S. In the fourth quarter, the ratio of SG&A to sales decreased 0.9 percentage points to 30.2% compared to the fourth quarter of 2017. Full-year SG&A expenses decreased 2.4% to €9,831 million (up 1.6% at CER). In 2018, the ratio of SG&A to sales was 28.5%, 0.2 percentage points lower than in 2017.
Fourth-quarter other current operating income net of expenses was -€148 million versus -€114 million in the fourth quarter of 2017 and included the share of profit/loss to Regeneron of the monoclonal antibodies Alliance net of associated marketing expenses incurred by Regeneron. In the fourth quarter of 2018, this line also included charges related to a legal contingency provision, as well as a capital gain on an associate company and other accruals, which in aggregate represented a net charge of €72 million. In the fourth quarter of 2017, this line included an impairment of tangible assets of €87 million related to Dengvaxia®. In 2018, other current operating income net of expenses was -€64 million versus €4 million in 2017.
The share of profits from associates was €121 million in the fourth quarter versus €109 million for the same period of 2017, reflecting the increased contribution of the share of profits in Regeneron. In 2018, the share of profits from associates was €423 million versus €214 million in 2017.
In the fourth quarter, non-controlling interests were -€22 million versus -€30 million in the fourth quarter of 2017. Full-year non-controlling interests were -€106 million versus -€125 million in 2017.
Fourth-quarter business operating income increased 3.3% to €1,740 million. At CER, business operating income increased 4.5%. The ratio of business operating income to net sales decreased 0.1 percentage points to 19.3% versus the fourth quarter of 2017. Over the period, the business operating income ratio of segments was 27.1% for Pharmaceuticals (down 3.9 percentage points), 29.0% for CHC (up 2.2 percentage points) and 36.1% for Vaccines (up 14.2 percentage points). Full-year business operating income was €8,884 million, down 4.7% (or up 0.9% at CER). In 2018, the ratio of business operating income to net sales decreased by 0.8 percentage points to 25.8%.
Net financial expenses were -€60 million in the fourth quarter versus -€73 million in the same period of 2017. In the fourth quarter of 2018, net financial expenses included the cost associated with the Bioverativ and Ablynx acquisitions coupled with an increase of €22 million in the market value of a financial investment. Full-year net financial expenses were -€271 million versus -€273 million in 2017.
The fourth-quarter effective tax rate was 20.0% compared to 18.7% in the fourth quarter of 2017. In 2018, the effective tax rate was 21.6% compared to 23.5% in 2017. Sanofi expects its effective tax rate to be around 22% in 2019.
(11) See Appendix 3 for 2018 fourth-quarter consolidated income statement; see Appendix 10 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income.
Fourth-quarter business net income(11) increased 2.9% to €1,364 million and 4.3% at CER. The ratio of business net income to net sales was stable at 15.2% versus the fourth quarter of 2017. In 2018, business net income(11) decreased 1.8% to €6,819 million and increased 4.2% at CER. The ratio of business net income to net sales was stable at 19.8%.
| In the fourth quarter of 2018, business earnings per share(11) (EPS) increased by 3.8% to €1.10 on a reported basis and by 4.7% at CER. The average number of shares outstanding was 1,245.6 million in the fourth quarter of 2018 versus 1,252.9 million in the fourth quarter of 2017. In 2018, business earnings per share(11) was €5.47, down 0.9% on a reported basis and up 5.1% at CER. The average number of shares outstanding was 1,247.1 million in 2018 versus 1,256.9 million in 2017. |
2019 Guidance
Sanofi expects 2019 Business EPS to grow between 3% and 5% at CER, barring unforeseen major adverse events. Applying average January 2019 exchange rates, the positive currency impact on 2019 Business EPS is estimated to be between 1% to 2%.
Dividend
The Board of Directors convened on February 6, 2019, and proposed a dividend of €3.07 per share.
Financial statements are not audited. The audit procedures by the Statutory Auditors are underway.
Reconciliation of IFRS net income reported to business net income (see Appendix 4)
In 2018, the IFRS net income was €4,306 million. The main items excluded from the business net income were:
- An amortization charge of €2,170 million related to fair value remeasurement on intangible assets of acquired companies (primarily Aventis: €256 million, Genzyme: €760 million, Boehringer Ingelheim CHC business:
€242 million, Bioverativ: €430 million) and to acquired intangible assets (licenses/products: €213 million). In the fourth quarter, an amortization charge of €634 million related to fair value remeasurement on intangible assets of acquired companies (primarily Aventis: €56 million, Genzyme: €186 million, Boehringer Ingelheim CHC business: €61 million, Bioverativ: €136 million) and to acquired intangible assets (licenses/products: €114 million) was recorded. These items have no cash impact on the Company.
- An impairment of intangible assets of €718 million (of which €426 million in the fourth quarter) mainly related to Lemtrada®, intangible assets from the Ablynx acquisition in May 2018 (including the anticipated termination collaboration with Merck & Co), and other Intellectual Property R&D assets of which the rights related to programs in Myokardia portfolio. This item has no cash impact on the Company.
- A charge of €114 million arising from the workdown of inventories of acquired companies (related to Bioverativ) remeasured at fair value due to the application of purchase accounting to acquisitions. This item has no cash impact on the Group.
- An income of €117 million mainly reflecting a decrease of Bayer contingent considerations linked to Lemtrada® (income of €109 million) and a charge related to CVR fair value adjustment.
- Restructuring costs and similar items of €1,480 million (of which €765 million in the fourth quarter) which include the termination fee (€283 million) paid to Regeneron related to the research program under the original IO agreement, streamlining initiatives in Europe and Japan, the cost of transfer to Evotec of the early stage infectious diseases R&D portfolio and Research unit for an amount of €252 million and accelerated depreciation of industrial assets in the U.S.
(11) See Appendix 3 for 2018 fourth-quarter consolidated income statement; see Appendix 10 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income.
- A €1,125 million tax effect arising from the items listed above, mainly comprising €692 million of deferred taxes generated by amortization and impairments of intangible assets, and €435 million associated with restructuring costs and similar items. The fourth-quarter tax effect was €503 million, including €241 million of deferred taxes on amortization and impairments charged against intangible assets and €220 million associated with restructuring costs and similar items (see Appendix 4).
- A €188 million tax effect (of which €56 million in the fourth quarter) arising from the U.S. tax reform.
- An income of €76 million net of tax (of which €180 million in the fourth quarter) related to restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures.
Capital Allocation
In 2018, net cash generated by operating activities was €5,061 million after capital expenditures of €1,674 million and an increase in working capital of €1,099 million. In 2018, restructuring costs and similar items were €894 million while expenditure on share repurchases was €1,104 million. Over the period, the dividend paid by Sanofi amounted to €3,773 million and acquisitions and partnerships net of disposals were €11,243 million (including €12,728 million related to the Bioverativ and Ablynx acquisitions and €1,598 million related to the European generics business divestment). As a consequence, net debt increased from €5,161 million at December 31, 2017, to €17,628 million at December 31, 2018 (amount net of €6,925 million in cash and cash equivalents).
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions, and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Appendices
List of appendices
| Appendix 1: | 2018 fourth-quarter and 2018 net sales by GBU, franchise, geographic region and product |
| Appendix 2: | 2018 fourth-quarter and 2018 business net income statement |
| Appendix 3: | 2018 fourth-quarter and 2018 consolidated income statement |
| Appendix 4: | Reconciliation of IFRS net income reported to business net income |
| Appendix 5 Appendix 6 Appendix 7: Appendix 8: Appendix 9: | Change in net debt Simplified consolidated balance sheet Currency sensitivity R&D pipeline Expected R&D milestones |
| Appendix 10: | Definitions of non-GAAP financial indicators |
Appendix 1: 2018 fourth-quarter net sales by GBU, franchise, geographic region and product
| Q4 2018 (€ million) | Total GBUs | % CER | % reported | Europe | % CER | United States | % CER | Rest of the World | % CER | Emerging Markets | % CER | Total Franchises | % CER | % reported |
| Aubagio | 436 | 12 .4% | 15 .0% | 108 | 12 .5% | 311 | 13 .5% | 17 | -5 .9% | 10 | 20 .0% | 446 | 12 .6% | 14 .7% |
| Lemtrada | 87 | -17 .1% | -17 .1% | 37 | -11 .9% | 45 | -19 .6% | 5 | -28 .6% | 9 | 28 .6% | 96 | -14 .3% | -14 .3% |
| Total MS | 523 | 6 .0% | 8 .1% | 145 | 5 .1% | 356 | 7 .8% | 22 | -12 .5% | 19 | 23 .5% | 542 | 6 .6% | 8 .2% |
| Cerezyme | 127 | -1 .6% | -0 .8% | 72 | -2 .7% | 47 | 4 .7% | 8 | -18 .2% | 63 | 34 .5% | 190 | 9 .3% | 3 .8% |
| Cerdelga | 43 | 31 .3% | 34 .4% | 16 | 87 .5% | 26 | 0 .0% | 1 | - | 1 | 100 .0% | 44 | 33 .3% | 33 .3% |
| Myozyme | 190 | 8 .0% | 9 .2% | 96 | 1 .1% | 79 | 18 .8% | 15 | 6 .7% | 36 | 25 .8% | 226 | 10 .7% | 10 .2% |
| Fabrazyme | 180 | 9 .3% | 11 .1% | 45 | 4 .8% | 104 | 9 .9% | 31 | 13 .8% | 26 | 61 .1% | 206 | 14 .4% | 14 .4% |
| Aldurazyme | 39 | 8 .3% | 8 .3% | 20 | 5 .3% | 12 | 20 .0% | 7 | 0 .0% | 15 | 41 .7% | 54 | 16 .7% | 12 .5% |
| Total Rare Disease | 644 | 6 .2% | 7 .9% | 262 | 3 .1% | 292 | 8 .5% | 90 | 8 .4% | 150 | 32 .6% | 794 | 10 .9% | 9 .4% |
| Taxotere | 6 | -25 .0% | -25 .0% | 1 | - | -1 | - | 6 | -25 .0% | 32 | 3 .1% | 38 | -2 .5% | -5 .0% |
| Jevtana | 109 | 16 .1% | 17 .2% | 41 | 10 .5% | 50 | 20 .0% | 18 | 20 .0% | 5 | -16 .7% | 114 | 14 .1% | 15 .2% |
| Eloxatine | 8 | -12 .5% | 0 .0% | 0 | -100 .0% | 0 | - | 8 | 0 .0% | 35 | 2 .8% | 43 | 0 .0% | -2 .3% |
| Thymoglobulin | 59 | 7 .4% | 9 .3% | 9 | 0 .0% | 43 | 5 .0% | 7 | 40 .0% | 19 | 17 .6% | 78 | 9 .9% | 9 .9% |
| Mozobil | 44 | 16 .2% | 18 .9% | 12 | 18 .2% | 26 | 18 .2% | 6 | 0 .0% | 3 | 0 .0% | 47 | 15 .0% | 17 .5% |
| Total Oncology | 286 | 9 .3% | 10 .4% | 89 | 10 .8% | 141 | 8 .7% | 56 | 8 .0% | 101 | 5 .0% | 387 | 8 .1% | 7 .8% |
| Dupixent | 278 | 128 .8% | 135 .6% | 29 | 2800 .0% | 225 | 87 .9% | 24 | 2200 .0% | 2 | - | 280 | 130 .5% | 137 .3% |
| Kevzara | 31 | 275 .0% | 287 .5% | 6 | 500 .0% | 23 | 214 .3% | 2 | - | 0 | - | 31 | 275 .0% | 287 .5% |
| Total Immunology | 309 | 138 .1% | 145 .2% | 35 | - | 248 | 95 .1% | 26 | - | 2 | - | 311 | 139 .7% | 146 .8% |
| Alprolix | 95 | - | - | 0 | - | 76 | - | 19 | - | 0 | - | 95 | - | - |
| Eloctate | 194 | - | - | 0 | - | 160 | - | 34 | - | 2 | - | 196 | - | - |
| Total Hemophilia Rare blood disorders | 292 | - | - | 3 | - | 236 | - | 53 | - | 2 | - | 294 | - | - |
| Sanofi Genzyme (Specialty Care) | 2,054 | 37 .4% | 40 .1% | 534 | 12 .6% | 1,273 | 48 .8% | 247 | 52 .5% | 274 | 22 .4% | 2,328 | 35 .2% | 36 .0% |
| Lantus | 624 | -27 .3% | -25 .9% | 168 | -8 .2% | 379 | -37 .0% | 77 | 1 .3% | 242 | 7 .7% | 866 | -19 .7% | -19 .5% |
| Toujeo | 180 | -6 .8% | -5 .8% | 77 | 23 .8% | 81 | -29 .1% | 22 | 22 .2% | 31 | 32 .0% | 211 | -2 .3% | -2 .3% |
| Apidra | 60 | -13 .0% | -13 .0% | 34 | 0 .0% | 17 | -36 .0% | 9 | 0 .0% | 29 | 10 .7% | 89 | -6 .2% | -8 .2% |
| Amaryl | 11 | -14 .3% | -21 .4% | 4 | -20 .0% | 1 | 0 .0% | 6 | -12 .5% | 66 | 1 .5% | 77 | -1 .3% | -3 .8% |
| Admelog | 57 | 5400 .0% | 5600 .0% | 2 | 100 .0% | 54 | - | 1 | - | 0 | - | 57 | 5400 .0% | 5600 .0% |
| Total Diabetes | 999 | -16 .2% | -14 .6% | 320 | -0 .6% | 555 | -26 .3% | 124 | 4 .3% | 376 | 7 .7% | 1,375 | -10 .5% | -10 .3% |
| Multaq | 93 | 22 .7% | 24 .0% | 10 | 0 .0% | 82 | 23 .1% | 1 | - | 2 | -50 .0% | 95 | 20 .8% | 23 .4% |
| Praluent | 78 | 48 .1% | 50 .0% | 23 | 53 .3% | 52 | 45 .7% | 3 | 50 .0% | 4 | 200 .0% | 82 | 50 .9% | 54 .7% |
| Total Cardiovascular | 171 | 33 .1% | 34 .6% | 33 | 32 .0% | 134 | 31 .0% | 4 | 150 .0% | 6 | 33 .3% | 177 | 33 .1% | 36 .2% |
| Diabetes & Cardiovascular | 1,170 | -11 .3% | -9 .8% | 353 | 1 .7% | 689 | -19 .4% | 128 | 6 .7% | 382 | 7 .9% | 1,552 | -7 .1% | -6 .7% |
| Plavix | 328 | -4 .9% | -5 .7% | 37 | 2 .9% | 0 | -100 .0% | 53 | -23 .5% | 238 | -0 .4% | 328 | -4 .9% | -5 .7% |
| Lovenox | 346 | -9 .0% | -10 .8% | 199 | -13 .9% | 9 | -28 .6% | 21 | -13 .0% | 117 | 3 .3% | 346 | -9 .0% | -10 .8% |
| Renagel / Renvela | 96 | -39 .4% | -38 .1% | 14 | -18 .8% | 57 | -53 .0% | 8 | 28 .6% | 17 | 13 .3% | 96 | -39 .4% | -38 .1% |
| Aprovel | 151 | -2 .5% | -4 .4% | 27 | -3 .7% | 3 | 50 .0% | 9 | -54 .2% | 112 | 8 .6% | 151 | -2 .5% | -4 .4% |
| Allegra | 26 | -21 .9% | -18 .8% | 1 | -50 .0% | 0 | - | 25 | -20 .0% | 0 | - | 26 | -21 .9% | -18 .8% |
| Myslee / Ambien / Stilnox | 59 | -1 .7% | 0 .0% | 11 | 10 .0% | 12 | -26 .7% | 21 | -13 .0% | 15 | 45 .5% | 59 | -1 .7% | 0 .0% |
| Synvisc / Synvisc One | 81 | -7 .0% | -5 .8% | 7 | 0 .0% | 55 | -13 .1% | 3 | 0 .0% | 16 | 14 .3% | 81 | -7 .0% | -5 .8% |
| Depakine | 109 | -0 .9% | -2 .7% | 39 | -2 .4% | 0 | - | 5 | -25 .0% | 65 | 1 .5% | 109 | -0 .9% | -2 .7% |
| Tritace | 54 | -8 .2% | -11 .5% | 35 | -7 .7% | 0 | - | 1 | -50 .0% | 18 | -5 .0% | 54 | -8 .2% | -11 .5% |
| Other Rx Drugs | 876 | -2 .3% | -4 .1% | 447 | -4 .3% | 49 | -4 .2% | 94 | -4 .2% | 286 | 1 .7% | 876 | -2 .3% | -4 .1% |
| Total Established Rx Products | 2,126 | -6 .8% | -8 .0% | 817 | -6 .8% | 185 | -31 .0% | 240 | -16 .0% | 884 | 2 .9% | 2,126 | -6 .8% | -8 .0% |
| Generics | 270 | -33 .8% | -37 .5% | 32 | -82 .9% | 45 | 5 .0% | 20 | 0 .0% | 173 | 3 .8% | 270 | -33 .8% | -37 .5% |
| Total Emerging Markets Specialty Care | 274 | 22 .4% | 11 .4% | 0 | - | 0 | - | 19 | 23 .5% | 274 | 22 .4% | 274 | 0 | 0 |
| Total Emerging Markets Diabetes & Cardiovascular | 382 | 7 .9% | 4 .4% | 0 | 0 | 0 | 382 | 7 .9% | 0 .0% | |||||
| General Medicines & Emerging Markets | 3,052 | -6 .6% | -9 .1% | 849 | -20 .2% | 230 | -26 .2% | 260 | -14 .9% | 1,713 | 6 .9% | 2,396 | -11 .1% | -12 .7% |
| Total Pharmaceuticals | 6,276 | 3 .0% | 2 .6% | 1,736 | -7 .8% | 2,192 | 8 .5% | 635 | 7 .9% | 1,713 | 6 .9% | 6,276 | 3 .0% | 2 .6% |
| Allergy, Cough and Cold | 268 | -6 .3% | -6 .6% | 91 | -13 .3% | 62 | -4 .8% | 29 | 11 .1% | 86 | -4 .3% | 268 | -6 .3% | -6 .6% |
| Pain | 336 | 4 .6% | 2 .1% | 147 | 3 .5% | 45 | 10 .0% | 33 | 3 .3% | 111 | 4 .3% | 336 | 4 .6% | 2 .1% |
| Digestive | 256 | 4 .4% | 2 .4% | 82 | 0 .0% | 53 | 10 .9% | 12 | -18 .8% | 109 | 8 .5% | 256 | 4 .4% | 2 .4% |
| Nutritional | 174 | 9 .1% | 6 .1% | 33 | 3 .1% | 10 | 0 .0% | 62 | 3 .2% | 69 | 19 .7% | 174 | 9 .1% | 6 .1% |
| Consumer Healthcare | 1,194 | 1 .9% | 0 .5% | 368 | -3 .6% | 274 | 6 .0% | 147 | -2 .7% | 405 | 6 .4% | 1,194 | 1 .9% | 0 .5% |
| Polio / Pertussis / Hib | 504 | 3 .0% | 2 .2% | 83 | -2 .4% | 102 | -9 .2% | 32 | -24 .4% | 287 | 14 .3% | 504 | 3 .0% | 2 .2% |
| Adult Booster Vaccines | 135 | -2 .9% | -1 .5% | 33 | -8 .3% | 76 | -6 .3% | 8 | 0 .0% | 18 | 26 .7% | 135 | -2 .9% | -1 .5% |
| Meningitis/Pneumonia | 131 | 59 .3% | 61 .7% | 0 | - | 80 | 45 .3% | 5 | 0 .0% | 46 | 104 .3% | 131 | 59 .3% | 61 .7% |
| Influenza Vaccines | 596 | 17 .1% | 18 .7% | 93 | 95 .8% | 411 | 24 .1% | 26 | 212 .5% | 66 | -44 .7% | 596 | 17 .1% | 18 .7% |
| Travel And Other Endemics Vaccines | 130 | -18 .8% | -18 .8% | 27 | 7 .7% | 33 | -32 .7% | 15 | 7 .7% | 55 | -23 .6% | 130 | -18 .8% | -18 .8% |
| Vaccines | 1,527 | 9 .7% | 10 .3% | 238 | 21 .9% | 729 | 10 .4% | 87 | 15 .8% | 473 | 2 .5% | 1,527 | 9 .7% | 10 .3% |
| Total Company | 8,997 | 3 .9% | 3 .5% | 2,342 | -4 .8% | 3,195 | 8 .7% | 869 | 6 .7% | 2,591 | 6 .0% | 8,997 | 3 .9% | 3 .5% |
2018 net sales by GBU, franchise, geographic region and product
| 2018 (€ million) | Total GBUs | % CER | % reported | Europe | % CER | United States | % CER | Rest of the World | % CER | Emerging Markets | % CER | Total Franchises | % CER | % reported |
| Aubagio | 1,599 | 8 .0% | 4 .5% | 385 | -0 .3% | 1,157 | 11 .4% | 57 | 0 .0% | 48 | 59 .5% | 1,647 | 9 .3% | 5 .1% |
| Lemtrada | 375 | -14 .0% | -16 .7% | 167 | -3 .4% | 189 | -19 .1% | 19 | -33 .3% | 27 | 33 .3% | 402 | -11 .6% | -15 .2% |
| Total MS | 1,974 | 3 .0% | -0 .3% | 552 | -1 .2% | 1,346 | 5 .8% | 76 | -11 .2% | 75 | 49 .2% | 2,049 | 4 .4% | 0 .4% |
| Cerezyme | 481 | -1 .8% | -4 .0% | 270 | -3 .6% | 174 | 2 .8% | 37 | -9 .3% | 230 | 24 .3% | 711 | 6 .4% | -2 .7% |
| Cerdelga | 156 | 28 .8% | 24 .8% | 51 | 96 .2% | 98 | 7 .4% | 7 | 100 .0% | 3 | 300 .0% | 159 | 31 .0% | 26 .2% |
| Myozyme | 716 | 8 .8% | 6 .4% | 374 | 6 .5% | 284 | 13 .0% | 58 | 3 .4% | 124 | 22 .4% | 840 | 10 .8% | 6 .5% |
| Fabrazyme | 673 | 7 .9% | 4 .5% | 175 | 7 .4% | 383 | 8 .1% | 115 | 8 .0% | 82 | 25 .6% | 755 | 9 .8% | 4 .6% |
| Aldurazyme | 144 | 4 .2% | 1 .4% | 76 | 1 .3% | 44 | 9 .5% | 24 | 4 .0% | 62 | 12 .1% | 206 | 6 .7% | -1 .0% |
| Total Rare Disease | 2,416 | 5 .3% | 2 .6% | 1,008 | 5 .3% | 1,072 | 5 .8% | 336 | 3 .6% | 542 | 21 .5% | 2,958 | 8 .3% | 2 .4% |
| Taxotere | 32 | -13 .5% | -13 .5% | 3 | 0 .0% | 1 | - | 28 | -17 .6% | 134 | 2 .9% | 166 | -0 .6% | -4 .0% |
| Jevtana | 399 | 13 .9% | 10 .8% | 158 | 7 .4% | 179 | 17 .6% | 62 | 20 .8% | 23 | 0 .0% | 422 | 13 .0% | 9 .3% |
| Eloxatine | 32 | -3 .0% | -3 .0% | 2 | -50 .0% | 0 | -100 .0% | 30 | 7 .1% | 150 | 6 .8% | 182 | 5 .0% | 1 .7% |
| Thymoglobulin | 222 | 2 .7% | -0 .9% | 37 | -5 .1% | 162 | 4 .9% | 23 | 0 .0% | 75 | 22 .7% | 297 | 7 .2% | 2 .4% |
| Mozobil | 161 | 7 .8% | 4 .5% | 47 | 9 .1% | 96 | 5 .2% | 18 | 21 .4% | 10 | 22 .2% | 171 | 8 .6% | 4 .9% |
| Total Oncology | 1,075 | -0 .4% | -3 .2% | 351 | 4 .1% | 523 | -6 .8% | 201 | 12 .2% | 419 | 8 .8% | 1,494 | 2 .1% | -1 .5% |
| Dupixent | 783 | 265 .8% | 257 .5% | 75 | 3650 .0% | 660 | 213 .9% | 48 | 4700 .0% | 5 | - | 788 | 268 .0% | 259 .8% |
| Kevzara | 83 | 663 .6% | 654 .5% | 14 | 1300 .0% | 64 | 550 .0% | 5 | - | 0 | - | 83 | 663 .6% | 654 .5% |
| Total Immunology | 866 | 284 .8% | 276 .5% | 89 | - | 724 | 228 .8% | 53 | - | 5 | - | 871 | 287 .0% | 278 .7% |
| Alprolix | 285 | - | - | 0 | - | 222 | - | 63 | - | 0 | - | 285 | - | - |
| Eloctate | 606 | - | - | 0 | - | 500 | - | 106 | - | 2 | - | 608 | - | - |
| Total Hemophilia Rare blood disorders | 895 | - | - | 4 | - | 722 | - | 169 | - | 2 | - | 897 | - | - |
| Sanofi Genzyme (Specialty Care) | 7,226 | 30 .8% | 27 .4% | 2,004 | 7 .9% | 4,387 | 42 .3% | 835 | 40 .9% | 1,043 | 18 .7% | 8,269 | 29 .0% | 23 .8% |
| Lantus | 2,588 | -25 .8% | -28 .4% | 684 | -9 .7% | 1,614 | -33 .3% | 290 | -3 .8% | 977 | 5 .3% | 3,565 | -19 .0% | -22 .9% |
| Toujeo | 710 | -0 .9% | -3 .7% | 290 | 34 .6% | 344 | -20 .7% | 76 | 18 .5% | 130 | 83 .5% | 840 | 7 .2% | 2 .9% |
| Apidra | 248 | -9 .0% | -11 .1% | 136 | 0 .0% | 74 | -23 .5% | 38 | -2 .4% | 109 | 26 .5% | 357 | 0 .3% | -5 .3% |
| Amaryl | 47 | -16 .9% | -20 .3% | 17 | -19 .0% | 2 | 0 .0% | 28 | -16 .7% | 288 | 9 .4% | 335 | 4 .8% | -0 .3% |
| Admelog | 93 | 9100 .0% | 9200 .0% | 7 | 600 .0% | 86 | - | 0 | - | 0 | - | 93 | 9100 .0% | 9200 .0% |
| Total Diabetes | 3,918 | -17 .5% | -20 .0% | 1,272 | -0 .9% | 2,185 | -26 .9% | 461 | -0 .8% | 1,554 | 12 .7% | 5,472 | -10 .4% | -14 .5% |
| Multaq | 343 | 7 .2% | 3 .3% | 43 | 2 .4% | 296 | 8 .0% | 4 | 0 .0% | 7 | 0 .0% | 350 | 7 .1% | 3 .2% |
| Praluent | 250 | 53 .3% | 49 .7% | 86 | 87 .0% | 154 | 37 .1% | 10 | 120 .0% | 11 | 175 .0% | 261 | 56 .1% | 52 .6% |
| Total Cardiovascular | 593 | 22 .6% | 18 .8% | 129 | 46 .6% | 450 | 16 .4% | 14 | 66 .7% | 18 | 63 .6% | 611 | 23 .5% | 19 .8% |
| Diabetes & Cardiovascular | 4,511 | -13 .8% | -16 .4% | 1,401 | 2 .2% | 2,635 | -22 .0% | 475 | 0 .4% | 1,572 | 13 .1% | 6,083 | -7 .9% | -11 .9% |
| Plavix | 1,440 | 1 .2% | -2 .0% | 147 | -2 .0% | 0 | -100 .0% | 218 | -23 .5% | 1,075 | 8 .8% | 1,440 | 1 .2% | -2 .0% |
| Lovenox | 1,465 | -3 .0% | -6 .9% | 870 | -8 .3% | 38 | -29 .3% | 81 | -6 .6% | 476 | 11 .4% | 1,465 | -3 .0% | -6 .9% |
| Renagel / Renvela | 411 | -46 .7% | -48 .7% | 60 | -15 .5% | 253 | -59 .1% | 31 | -8 .6% | 67 | 42 .0% | 411 | -46 .7% | -48 .7% |
| Aprovel | 652 | -1 .7% | -5 .5% | 108 | -6 .1% | 10 | 0 .0% | 69 | -45 .5% | 465 | 12 .7% | 652 | -1 .7% | -5 .5% |
| Allegra | 124 | -17 .7% | -21 .5% | 8 | -11 .1% | 0 | - | 116 | -18 .1% | 0 | - | 124 | -17 .7% | -21 .5% |
| Myslee / Ambien / Stilnox | 231 | -6 .9% | -10 .8% | 39 | -2 .5% | 45 | -14 .5% | 86 | -16 .0% | 61 | 13 .8% | 231 | -6 .9% | -10 .8% |
| Synvisc / Synvisc One | 313 | -15 .0% | -19 .1% | 25 | -16 .7% | 217 | -22 .3% | 13 | 0 .0% | 58 | 23 .5% | 313 | -15 .0% | -19 .1% |
| Depakine | 452 | 4 .7% | 1 .1% | 163 | -1 .2% | 0 | - | 14 | -6 .7% | 275 | 9 .0% | 452 | 4 .7% | 1 .1% |
| Tritace | 221 | -3 .8% | -7 .9% | 142 | -5 .9% | 0 | - | 5 | 0 .0% | 74 | 0 .0% | 221 | -3 .8% | -7 .9% |
| Other Rx Drugs | 3,534 | -2 .5% | -6 .8% | 1,768 | -2 .0% | 188 | -6 .3% | 376 | -7 .1% | 1,202 | -1 .1% | 3,534 | -2 .5% | -6 .8% |
| Total Established Rx Products | 8,843 | -6 .1% | -9 .9% | 3,330 | -4 .4% | 751 | -38 .2% | 1,009 | -16 .9% | 3,753 | 6 .6% | 8,843 | -6 .1% | -9 .9% |
| Generics | 1,490 | -9 .8% | -15 .8% | 568 | -24 .4% | 124 | -15 .3% | 113 | 9 .1% | 685 | 3 .0% | 1,490 | -9 .8% | -15 .8% |
| Total Emerging Markets Specialty Care | 1,043 | 18 .7% | 3 .9% | 0 | - | 0 | - | 75 | 49 .2% | 1,043 | 18 .7% | |||
| Total Emerging Markets Diabetes & Cardiovascular | 1,572 | 13 .1% | 4 .2% | 1,572 | 13 .1% | |||||||||
| General Medicines & Emerging Markets | 12,948 | -2 .8% | -8 .2% | 3,898 | -7 .9% | 875 | -35 .8% | 1,122 | -14 .8% | 7,053 | 9 .3% | 10,333 | -6 .7% | -10 .8% |
| Total Pharmaceuticals | 24,685 | 2 .4% | -1 .9% | 7,303 | -2 .1% | 7,897 | 0 .9% | 2,432 | 1 .9% | 7,053 | 9 .3% | 24,685 | 2 .4% | -1 .9% |
| Allergy, Cough and Cold | 1,124 | -1 .7% | -6 .7% | 347 | -0 .9% | 303 | -12 .3% | 135 | 2 .9% | 339 | 6 .9% | 1,124 | -1 .7% | -6 .7% |
| Pain | 1,254 | 6 .7% | -0 .6% | 521 | 1 .8% | 165 | 3 .6% | 119 | 3 .4% | 449 | 14 .0% | 1,254 | 6 .7% | -0 .6% |
| Digestive | 986 | 8 .7% | 3 .4% | 314 | 2 .6% | 195 | 8 .5% | 54 | 1 .8% | 423 | 14 .4% | 986 | 8 .7% | 3 .4% |
| Nutritional | 675 | 4 .7% | -1 .5% | 125 | 5 .9% | 37 | -5 .0% | 256 | 5 .9% | 257 | 4 .4% | 675 | 4 .7% | -1 .5% |
| Consumer Healthcare | 4,660 | 3 .0% | -2 .9% | 1,403 | -0 .2% | 1,066 | -1 .1% | 603 | 2 .1% | 1,588 | 8 .9% | 4,660 | 3 .0% | -2 .9% |
| Polio / Pertussis / Hib | 1,749 | -0 .7% | -4 .3% | 296 | -1 .0% | 397 | -4 .8% | 156 | 5 .9% | 900 | 0 .3% | 1,749 | -0 .7% | -4 .3% |
| Adult Booster Vaccines | 470 | 1 .3% | -0 .8% | 129 | 9 .2% | 273 | -4 .1% | 26 | 0 .0% | 42 | 18 .9% | 470 | 1 .3% | -0 .8% |
| Meningitis/Pneumonia | 609 | 0 .6% | -2 .2% | 0 | -100 .0% | 466 | -1 .6% | 16 | -50 .0% | 127 | 29 .1% | 609 | 0 .6% | -2 .2% |
| Influenza Vaccines | 1,708 | 7 .2% | 7 .5% | 177 | 57 .5% | 1,233 | 7 .5% | 81 | 62 .7% | 217 | -22 .9% | 1,708 | 7 .2% | 7 .5% |
| Travel And Other Endemics Vaccines | 488 | 1 .8% | -1 .0% | 117 | 31 .1% | 134 | -10 .3% | 56 | 7 .4% | 181 | -3 .6% | 488 | 1 .8% | -1 .0% |
| Vaccines | 5,118 | 2 .4% | 0 .3% | 728 | 16 .0% | 2,577 | 1 .1% | 342 | 9 .5% | 1,471 | -2 .3% | 5,118 | 2 .4% | 0 .3% |
| Total Company | 34,463 | 2 .5% | -1 .7% | 9,434 | -0 .6% | 11,540 | 0 .7% | 3,377 | 2 .7% | 10,112 | 7 .5% | 34,463 | 2 .5% | -1 .7% |
Appendix 2: Business net income statement
| Fourth Quarter 2018 | Pharmaceuticals | Consumer Healthcare | Vaccines | Others(2) | Total Group | ||||||||||
| € million | Q4 2018 | Q4 2017(1) | Cha- nge | Q4 2018 | Q4 2017(1) | Cha- nge | Q4 2018 | Q4 2017(1) | Cha- nge | Q4 2018 | Q4 2017(1) | Cha- nge | Q4 2018 | Q4 2017(1) | Cha- nge |
| Net sales | 6 ,276 | 6 ,119 | 2 .6% | 1 ,194 | 1 ,188 | 0 .5% | 1 ,527 | 1 ,385 | 10 .3% | - | - | 8 ,997 | 8 ,692 | 3 .5% | |
| Other revenues | 67 | 66 | 1 .5% | - | - | 262 | 224 | 17 .0% | - | - | 329 | 290 | 13 .4% | ||
| Cost of Sales | (1 ,820) | (1 ,760) | 3 .4% | (406) | (423) | (4 .0)% | (866) | (841) | 3 .0% | (46) | (75) | (38 .7)% | (3 ,138) | (3 ,099) | 1 .3% |
| As % of net sales | (29 .0)% | (28 .8)% | (34 .0)% | (35 .6)% | (56 .7)% | (60 .7)% | (34 .9)% | (35 .7)% | |||||||
| Gross Profit | 4 ,523 | 4 ,425 | 2 .2% | 788 | 765 | 3 .0% | 923 | 768 | 20 .2% | (46) | (75) | (38 .7%) | 6 ,188 | 5 ,883 | 5 .2% |
| As % of net sales | 72 .1% | 72 .3% | 66 .0% | 64 .4% | 60 .4% | 55 .5% | 68 .8% | 67 .7% | |||||||
| Research and development expenses | (1 ,311) | (1 ,067) | 22 .9% | (48) | (41) | 17 .1% | (162) | (166) | (2 .4)% | (157) | (190) | (17 .4)% | (1 ,678) | (1 ,464) | 14 .6% |
| As % of net sales | (20 .9)% | (17 .4)% | (4 .0)% | (3 .5)% | (10 .6)% | (12 .0)% | (18 .7)% | (16 .8)% | |||||||
| Selling and general expenses | (1 ,485) | (1 ,523) | (2 .5)% | (409) | (406) | 0 .7% | (210) | (197) | 6 .6% | (617) | (573) | 7 .7% | (2 ,721) | (2 ,699) | 0 .8% |
| As % of net sales | (23 .7)% | (24 .9)% | (34 .3)% | (34 .2)% | (13 .8)% | (14 .2)% | (30 .2)% | (31 .1)% | |||||||
| Other current operating income/ expenses | (123) | (19) | 16 | 2 | (1) | (100) | (40) | 3 | (148) | (114) | |||||
| Share of profit/loss of associates* and joint-ventures | 120 | 109 | - | 1 | 1 | (1) | - | - | 121 | 109 | |||||
| Net income attributable to non controlling interests | (21) | (26) | (1) | (3) | - | (1) | - | - | (22) | (30) | |||||
| Business operating income | 1 ,703 | 1 ,899 | (10 .3)% | 346 | 318 | 8 .8% | 551 | 303 | 81 .8% | (860) | (835) | 3 .0% | 1 ,740 | 1 ,685 | 3 .3% |
| As % of net sales | 27 .1% | 31 .0% | 29 .0% | 26 .8% | 36 .1% | 21 .9% | 19 .3% | 19 .4% | |||||||
| Financial income and expenses | (60) | (73) | |||||||||||||
| Income tax expenses | (316) | (287) | |||||||||||||
| Tax rate** | 20 .0% | 18 .7% | |||||||||||||
| Business net income | 1 ,364 | 1 ,325 | 2 .9% | ||||||||||||
| As % of net sales | 15 .2% | 15 .2% | |||||||||||||
| Business earnings / share (in euros)*** | 1 .10 | 1 .06 | 3 .8% | ||||||||||||
* Net of tax.
** Determined on the basis of Business income before tax, associates, and non-controlling interests.
*** Based on an average number of shares outstanding of 1,245.6 million in the fourth quarter of 2018 and 1,252.9 million in the fourth quarter of 2017.
(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018.
(2) Other includes the cost of Global Support Functions (Medical Affairs, External Affairs, Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc.).
| Full year 2018 | Pharmaceuticals | Consumer Healthcare | Vaccines | Others (2) | Total Group | ||||||||||
| € million | 2018 | 2017(1) | Cha- nge | 2018 | 2017(1) | Cha- nge | 2018 | 2017(1) | Cha- nge | 2018 | 2017(1) | Cha- nge | 2018 | 2017(1) | Cha- nge |
| Net sales | 24 ,685 | 25 ,173 | (1 .9)% | 4 ,660 | 4 ,798 | (2 .9)% | 5 ,118 | 5 ,101 | 0 .3% | - | - | 34 ,463 | 35 ,072 | (1 .7)% | |
| Other revenues | 252 | 287 | (12 .2)% | - | - | 962 | 862 | 11 .6% | - | - | 1 ,214 | 1 ,149 | 5 .7% | ||
| Cost of Sales | (6 ,738) | (6 ,766) | (0 .4)% | (1 ,539) | (1 ,612) | (4 .5)% | (2 ,854) | (2 ,798) | 2 .0% | (190) | (271) | (29 .9)% | (11 ,321) | (11 ,447) | (1 .1)% |
| As % of net sales | (27 .3)% | (26 .9)% | (33 .0)% | (33 .6)% | (55 .8)% | (54 .9)% | (32 .8)% | (32 .6)% | |||||||
| Gross Profit | 18 ,199 | 18 ,694 | (2 .6)% | 3 ,121 | 3 ,186 | (2 .0)% | 3 ,226 | 3 ,165 | 1 .9% | (190) | (271) | (29 .9%) | 24 ,356 | 24 ,774 | (1 .7)% |
| As % of net sales | 73 .7% | 74 .3% | 67 .0% | 66 .4% | 63 .0% | 62 .0% | 70 .7% | 70 .6% | |||||||
| Research and development expenses | (4 ,572) | (4 ,056) | 12 .7% | (143) | (123) | 16 .3% | (555) | (557) | (0 .4)% | (624) | (736) | (15 .2)% | (5 ,894) | (5 ,472) | 7 .7% |
| As % of net sales | (18 .5)% | (16 .1)% | (3 .1)% | (2 .6)% | (10 .8)% | (10 .9)% | (17 .1)% | (15 .6)% | |||||||
| Selling and general expenses | (5 ,431) | (5 ,649) | (3 .9)% | (1 ,534) | (1 ,645) | (6 .7)% | (710) | (728) | (2 .5)% | (2 ,156) | (2 ,050) | 5 .2% | (9 ,831) | (10 ,072) | (2 .4)% |
| As % of net sales | (22 .0)% | (22 .4)% | (32 .9)% | (34 .3)% | (13 .9)% | (14 .3)% | (28 .5)% | (28 .7)% | |||||||
| Other current operating income/ expenses | (37) | 34 | 101 | 94 | (4) | (107) | (124) | (17) | (64) | 4 | |||||
| Share of profit/loss of associates* and joint-ventures | 425 | 212 | 1 | 1 | (3) | 1 | - | - | 423 | 214 | |||||
| Net income attributable to non controlling interests | (96) | (110) | (10) | (15) | - | - | - | - | (106) | (125) | |||||
| Business operating income | 8 ,488 | 9 ,125 | (7 .0)% | 1 ,536 | 1 ,498 | 2 .5% | 1 ,954 | 1 ,774 | 10 .1% | (3 ,094) | (3 ,074) | 0 .7% | 8 ,884 | 9 ,323 | (4 .7)% |
| As % of net sales | 34 .4% | 36 .2% | 33 .0% | 31 .2% | 38 .2% | 34 .8% | 25 .8% | 26 .6% | |||||||
| Financial income and expenses | (271) | (273) | |||||||||||||
| Income tax expenses | (1 ,794) | (2 ,107) | |||||||||||||
| Tax rate** | 21 .6% | 23 .5% | |||||||||||||
| Business net income | 6 ,819 | 6 ,943 | (1 .8)% | ||||||||||||
| As % of net sales | 19 .8% | 19 .8% | |||||||||||||
| Business earnings / share (in euros)*** | 5 .47 | 5 .52 | (0 .9)% | ||||||||||||
* Net of tax.
** Determined on the basis of Business income before tax, associates, and non-controlling interests.
*** Based on an average number of shares outstanding of 1,247.1 million in 2018 and 1,256.9 million in 2017.
(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018.
(2) Other includes the cost of Global Support Functions (Medical Affairs, External Affairs, Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc.).
Appendix 3: Consolidated income statements
| € million | Q4 2018 | Q4 2017(1) | 2018 | 2017(1) |
| Net sales | 8,997 | 8,692 | 34,463 | 35,072 |
| Other revenues | 329 | 290 | 1,214 | 1,149 |
| Cost of sales | (3,138) | (3,089) | (11,435) | (11,613) |
| Gross profit | 6,188 | 5,893 | 24,242 | 24,608 |
| Research and development expenses | (1,678) | (1,464) | (5,894) | (5,472) |
| Selling and general expenses | (2,730) | (2,699) | (9,859) | (10,072) |
| Other operating income | 83 | 10 | 484 | 237 |
| Other operating expenses | (231) | (124) | (548) | (233) |
| Amortization of intangible assets | (634) | (442) | (2,170) | (1,866) |
| Impairment of intangible assets | (426) | (262) | (718) | (293) |
| Fair value remeasurement of contingent consideration | - | 15 | 117 | (159) |
| Restructuring costs and similar items | (765) | (118) | (1,480) | (731) |
| Other gains and losses, and litigation | (7) | (61) | 502 | (215) |
| Operating income | (200) | 748 | 4,676 | 5,804 |
| Financial expenses | (103) | (99) | (435) | (420) |
| Financial income | 43 | 26 | 164 | 147 |
| Income before tax and associates and joint ventures | (260) | 675 | 4,405 | 5,531 |
| Income tax expense | 243 | (699) | (481) | (1,722) |
| Share of profit/(loss) of associates and joint ventures | 301 | 21 | 499 | 85 |
| Net income excluding the exchanged/held-for-exchange Animal Health business | 284 | (3) | 4,423 | 3,894 |
| Net income/(loss) of the exchanged/held-for-exchange Animal Health business(2) | (9) | 159 | (13) | 4,643 |
| Net income | 275 | 156 | 4,410 | 8,537 |
| Net income attributable to non-controlling interests | 21 | 30 | 104 | 121 |
| Net income attributable to equity holders of Sanofi | 254 | 126 | 4,306 | 8,416 |
| Average number of shares outstanding (million) | 1,245.6 | 1,252.9 | 1,247.1 | 1,256.9 |
| Earnings per share excluding the exchanged/held-for-exchange Animal Health business (in euros) | 0.21 | (0.03) | 3.46 | 3.00 |
| IFRS Earnings per share (in euros) | 0.20 | 0.10 | 3.45 | 6.70 |
(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018.
(2) In 2017, net gain resulting from the divestment of the Animal Health business presented separately in accordance with IFRS 5, Non current assets held-for-sale and discontinued operations.
Appendix 4: Reconciliation of Net income attributable to equity holders of Sanofi to Business net income
| € million | Q4 2018 | Q4 2017(1) | Change | ||
| Net income attributable to equity holders of Sanofi | 254 | 126 | 101.6% | ||
| Amortization of intangible assets(2) | 634 | 442 | |||
| Impairment of intangible assets | 426 | 262 | |||
| Fair value remeasurement of contingent consideration | - | (15) | |||
| Expenses arising from the impact of acquisitions on inventories | - | (10) | |||
| Other expenses related to business combinations | 9 | - | |||
| Restructuring costs and similar items | 765 | 118 | |||
| Other gains and losses, and litigation | 7 | 61 | |||
| Tax effect of the items listed above(3): | (503) | (219) | |||
| Amortization and impairment of intangible assets | (241) | (242) | |||
| Fair value remeasurement of contingent consideration | 3 | 37 | |||
| Expenses arising from the impact of acquisitions on inventories | - | 4 | |||
| Other expenses related to business combinations | (2) | - | |||
| Restructuring costs and similar items | (220) | 82 | |||
| Other tax effects | (43) | (100) | |||
| Other tax items(4) | (56) | 631 | |||
| Share of items listed above attributable to non-controlling interests | (1) | - | |||
| Restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures | (180) | 88 | |||
| Animal Health items (5) | 9 | (159) | |||
| Business net income | 1,364 | 1,325 | 2.9% | ||
| IFRS earnings per share (6) (in euros) | 0.20 | 0.10 |
(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018.
(2) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €520 million in the fourth quarter of 2018 and €407 million in the fourth quarter of 2017.
(3) In 2017, this line includes the impact of changes in corporate income tax rates, mainly in France (25% standard rate effective as of January 1, 2022).
(4) In 2018, adjustments made to our preliminary analysis of the direct and indirect impacts of US tax reform. In 2017, includes an amount of €562m related to litigation gain on French 3% tax on dividends and temporary exceptional surcharge and an amount of (€1,193) million related to US tax reform.
(5) In 2017, net gain resulting from the divestment of the Animal Health business presented separately in accordance with IFRS 5, Non-current assets held-for-sale and discontinued operations (including the closing in Mexico in Q4 2017).
(6) Based on an average number of shares outstanding of 1,245.6 million in the fourth quarter of 2018 and 1,252.9 million in the fourth quarter of 2017.
| € million | 2018 | 2017(1) | Change | ||
| Net income attributable to equity holders of Sanofi | 4,306 | 8,416 | (48.8)% | ||
| Amortization of intangible assets(2) | 2,170 | 1,866 | |||
| Impairment of intangible assets | 718 | 293 | |||
| Fair value remeasurement of contingent consideration | (117) | 159 | |||
| Expenses arising from the impact of acquisitions on inventories | 114 | 166 | |||
| Other expenses related to business combinations | 28 | - | |||
| Restructuring costs and similar items | 1,480 | 731 | |||
| Other gains and losses, and litigation (3) | (502) | 215 | |||
| Tax effect of the items listed above(4): | (1,125) | (1,127) | |||
| Amortization and impairment of intangible assets | (692) | (719) | |||
| Fair value remeasurement of contingent consideration | 38 | 4 | |||
| Expenses arising from the impact of acquisitions on inventories | (27) | (52) | |||
| Other expenses related to business combinations | (6) | - | |||
| Restructuring costs and similar items | (435) | (134) | |||
| Other tax effects | (3) | (226) | |||
| Other tax items(5) | (188) | 742 | |||
| Share of items listed above attributable to non-controlling interests | (2) | (4) | |||
| Restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures | (76) | 129 | |||
| Animal Health items (6) | 13 | (4,643) | |||
| Business net income | 6,819 | 6,943 | (1.8)% | ||
| IFRS earnings per share (7) (in euros) | 3.45 | 6.70 |
(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018.
(2) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €1,957 million in 2018 and €1,726 million in 2017.
(3) In 2018, of which gain resulting from the European Generics business divestiture amounting to €510 million. In 2017, mainly adjustment to vendor's guarantee provision in connection with past divestment.
(4) In 2017, this line includes the impact of changes in corporate income tax rates, mainly in France (25% standard rate effective as of January 1, 2022).
(5) In 2018, adjustments made to our preliminary analysis of the direct and indirect impacts of US tax reform. In 2017, includes French 3% tax on dividends and temporary exceptional surcharge for an amount of €451 million and US tax reform amounting to €(1,193) million.
(6) In 2017, net gain resulting from the divestment of the Animal Health business presented separately in accordance with IFRS 5, Non-current assets held-for-sale and discontinued operations.
(7) Based on an average number of shares outstanding of 1,247.1 million in 2018 and 1,256.9 million in 2017.
Appendix 5: Change in net debt
| € million | 2018 | 2017(1) |
| Business net income | 6,819 | 6,943 |
| Depreciation, amortization and impairment of property, plant and equipment and software | 1,208 | 1,349 |
| Gains and losses on disposals of non-current assets, net of tax | (284) | (127) |
| Other non cash items | 91 | 728 |
| Operating cash flow before changes in working capital (2) | 7,834 | 8,893 |
| Changes in working capital (2) | (1,099) | (589) |
| Acquisitions of property, plant and equipment and software | (1,674) | (1,500) |
| Free cash flow (2) | 5,061 | 6,804 |
| Acquisitions of intangible assets excluding software | (312) | (398) |
| Acquisitions of investments in consolidated undertakings including assumed debt | (13,051) | (1,063) |
| Restructuring costs and similar items paid | (894) | (754) |
| Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of tax | 2,120 | 408 |
| Issuance of Sanofi shares | 177 | 319 |
| Dividends paid to shareholders of Sanofi | (3,773) | (3,710) |
| Acquisition of treasury shares | (1,104) | (2,158) |
| Transactions with non-controlling interests including dividends | (91) | (52) |
| Foreign exchange impact | (288) | 434 |
| Net cash-flow from the swap between BI - CHC and Sanofi Animal Health business | (6) | 3,535 |
| Other items | (306) | (292) |
| Change in net debt | (12,467) | 3,073 |
| (1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018. |
| (2) Excluding restructuring costs and similar items. |
Appendix 6: Simplified consolidated balance sheet
| ASSETS € million | Dec 31, 2018 | Dec 31, 2017(1) | LIABILITIES & EQUITY € million | Dec 31, 2018 | Dec 31, 2017(1) | |
| Equity attributable to equity holders of Sanofi | 58,876 | 58,070 | ||||
| Equity attributable to non-controlling interests | 159 | 169 | ||||
| Total equity | 59,035 | 58,239 | ||||
| Long-term debt | 22,007 | 14,326 | ||||
| Property, plant and equipment | 9,651 | 9,579 | Non-current liabilities related to business combinations and to non-controlling interests | 963 | 1,026 | |
| Intangible assets (including goodwill) | 66,124 | 53,344 | Provisions and other non-current liabilities | 8,613 | 9,154 | |
| Non-current financial assets & investments in associates and deferred tax assets | 10,986 | 10,502 | Deferred tax liabilities | 3,414 | 1,605 | |
| Non-current assets | 86,761 | 73,425 | Non-current liabilities | 34,997 | 26,111 | |
| Accounts payable & Other current liabilities | 14,402 | 13,845 | ||||
| Inventories, accounts receivable and other current assets | 17,654 | 16,039 | Current liabilities related to business combinations and to non-controlling interests | 341 | 343 | |
| Cash and cash equivalents | 6,925 | 10,315 | Short-term debt and current portion of long-term debt | 2,633 | 1,275 | |
| Current assets | 24,579 | 26,354 | Current liabilities | 17,376 | 15,463 | |
| Assets held for sale or exchange | 68 | 34 | Liabilities related to assets held for sale or exchange | - | - | |
| Total ASSETS | 111,408 | 99,813 | Total LIABILITIES & EQUITY | 111,408 | 99,813 |
(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018.
Appendix 7 : currency sensitivity
2019 Business EPS currency sensitivity
| Currency | Variation | Business EPS Sensitivity |
| U.S. Dollar | +0.05 USD/EUR | -EUR 0.10 |
| Japanese Yen | +5 JPY/EUR | -EUR 0.02 |
| Chinese Yuan | +0.2 CNY/EUR | -EUR 0.02 |
| Brazilian Real | +0.4 BRL/EUR | -EUR 0.01 |
| Russian Ruble | +10 RUB/EUR | -EUR 0.03 |
Currency exposure on Q4 2018 sales
| Currency | Q4 2018 |
| US $ | 36.6% |
| Euro € | 23.8% |
| Chinese Yuan | 6.2% |
| Japanese Yen | 4.7% |
| Brazilian Real | 2.7% |
| British Pound | 1.8% |
| Mexican Peso | 1.8% |
| Canadian $ | 1.8% |
| Russian Ruble | 1.7% |
| Australian $ | 1.4% |
| Others | 17.5% |
Currency average rates
| Q4 2017 | Q4 2018 | Change | |
| €/$ | 1.18 | 1.14 | -3.1% |
| €/Yen | 133.0 | 128.82 | -3.1% |
| €/Yuan | 7.79 | 7.90 | +1.4% |
| €/Real | 3.83 | 4.35 | +13.6% |
| €/Ruble | 68.80 | 75.91 | +10.3% |
Appendix 8: R&D Pipeline
O : Opt-in rights products for which rights have not been exercised yet
R : Registrational Study (other than Phase 3)
| Immuno-inflammation | Rare Blood Disorders | Cardiovascular & metabolism | |||
| Oncology | MS & Neuro | Vaccines | |||
| Rare Diseases | Diabetes |
New Molecular Entities(*)
| Phase 1 (Total : 17) | Phase 2 (Total : 7) | Phase 3 (Total : 7) | Registration (Total : 2) | ||||
| SAR441344 Anti-CD40L mAb Multiple Sclerosis | BIVV001(4) rFVIIIFc - vWF - XTEN(5) Hemophilia A | SAR440340(**) Anti-IL33 mAb Atopic Dermatitis | HIV Viral vector prime & rgp120 boost vaccine | isatuximab Anti-CD38 mAb 3L Relapsing Refractory MM (ICARIA) | cemiplimab(**) PD-1 inhibitor mAb Advanced CSCC (EU) | ||
| SAR408701 Maytansin-loaded anti-CEACAM5 mAb Solid Tumors | ST400(6) ZFN Gene Editing Technology Beta thalassemia | SAR156597 IL4/IL13 bispecific mAb Systemic Scleroderma | SP0232(**)(13) Respiratory syncytial virus Monoclonal Antibody | avalglucosidase alfa Neo GAA Pompe Disease | ZynquistaTM(**) Oral SGLT-1&2 inhibitor Type 1 Diabetes (U.S./EU) | ||
| SAR439459 anti-TGFb mAb Advanced Solid Tumors | BIVV003(6) ZFN Gene Editing Technology Sickle Cell Disease | R | olipudase alfa rhASM Acid Sphingomyelinase Deficiency(10) | venglustat Oral GCS inhibitor ADPKD(14) | |||
| O | REGN5458(1) Anti-BCMA-CD3 bispecific mAb RRMM | SAR442168(7)(**) BTK inhibitor Multiple Sclerosis | SAR339375(11) miRNA-21 Alport Syndrome | fitusiran RNAi therapeutic targeting anti-thrombin Hemophilia A and B | |||
| O | REGN4018(1) Anti-MUC16-CD3 bispecific mAb Ovarian Cancer | SAR443060(8) RIPK1 inh(9) Amyotrophic Lateral Sclerosis | SAR422459(**)(12) ABCA4 gene therapy Stargardt Disease | sutimlimab(15) Anti Complement C1s mAb Cold Agglutinin Disease | |||
| SAR439859 SERD Metastatic Breast Cancer | Next Gen PCV Pneumococcal Conjugate Vaccines | SAR341402 Rapid acting insulin Type 1/2 Diabetes | |||||
| SAR442720(2) SHP2 inhibitor Solid Tumors | Herpes Simplex Virus Type 2 HSV-2 vaccine | efpeglenatide(**) Long-acting GLP-1 agonist Type 2 Diabetes | |||||
| SAR440234 T cell engaging multi spe mAb Leukemia | Respiratory syncytial virus Infants Vaccines | ||||||
| SAR441000(3) Cytokine mRNA Melanoma | |||||||
| Regeneron product for which Sanofi has opt-in rights Developed in collaboration with REVOLUTION Medicines; also known as RMC-4630 Developed in collaboration with BioNtech Sanofi Product for which Sobi has opt-in rights Recombinant Coagulation Factor VIII Fc - von Willebrand Factor - XTEN Fusion protein Developed in collaboration with Sangamo Also known as PRN2246 Also known as DNL747 Receptor-interacting serine/threonine-protein kinase 1 | Also known as Niemann Pick type B Regulus product for which Sanofi has decided to opt-in Identification of out-licensing partner ongoing Also known as MEDI8897 Autosomal Dominant Polycystic Kidney Disease Also Known as BIVV009 (*) Phase of projects determined by clinicaltrials.gov disclosure timing (**) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products |
Additional Indications(*)
| Phase 1 (Total : 5) | Phase 2 (Total : 17) | Phase 3 (Total : 23) | Registration (Total : 3) | ||||
| SAR439459 + cemiplimab(**) Anti-TGFb mAb + PD-1 inhibitor mAb Advanced Solid Tumors | dupilumab(**) Anti-IL4Ralpha mAb Grass Immunotherapy | isatuximab + atezolizumab(**) Anti-CD38 mAb + PD-L1 inhibitor mAb Advanced Malignancies | dupilumab(**) Anti-IL4Ralpha mAb Asthma 6 - 11 years old | isatuximab Anti-CD38 mAb Newly Diagnosed MM Te(6) (GMMG) | dupilumab(**) Anti-IL4Ralpha mAb Asthma 12y+ (EU) | ||
| O | cemiplimab(**) + REGN4018(1) PD-1 inhibitor mAb + Anti-MUC16-CD3 bispecific mAb - Ovarian Cancer | R | sarilumab(**) Anti-IL6R mAb Polyarticular Juvenile Idiopathic Arthritis | isatuximab + atezolizumab(**) Anti-CD38 mAb + PD-L1 inhibitor mAb Solid Tumors | dupilumab(**) Anti-IL4Ralpha mAb Nasal Polyposis | isatuximab Anti-CD38 mAb 1-3L Relapsing Refractory MM (IKEMA) | Dupixent®(**) dupilumab Atopic Dermatitis 12 - 17 years old (U.S./EU) |
| SAR439859 SERD + Palbociclib Metastatic Breast Cancer | sarilumab(**) Anti-IL6R mAb Systemic Juvenile Arthritis | venglustat Oral GCS inhibitor Fabry Disease | dupilumab(**) Anti-IL4Ralpha mAb Eosinophilic Esophagitis | Aubagio® teriflunomide Relapsing Multiple Sclerosis - Pediatric | Praluent®(**) alirocumab CV events reduction (U.S./EU) | ||
| sutimlimab(2) Anti Complement C1s mAb Idiopathic Thrombocytopenic Purpura | SAR440340(**) Anti-IL33 mAb COPD | venglustat Oral GCS inhibitor Gaucher Type 3 | Dupixent®(**) dupilumab Atopic Dermatitis 6 - 11 years old | Lemtrada® alemtuzumab Relapsing Remitting Multiple Sclerosis - Pediatric | |||
| SAR443060(3) RIPK1 inh(4) Alzheimer's Disease | dupilumab(**) + AR101 Anti-IL4Ralpha mAb Peanut Allergy - Pediatric | venglustat Oral GCS inhibitor Gaucher related Parkinson's Disease | Dupixent®(**) dupilumab Atopic Dermatitis 6 months - 5 years old | ZynquistaTM(**) Oral SGLT-1&2 inhibitor Worsening Heart Failure in Diabetes | |||
| SAR440340(**) Anti-IL33 mAb Asthma | Rabies VRVg Purified vero rabies vaccine | sarilumab(**) Anti-IL6R mAb Giant Cell Arteritis | ZynquistaTM(**) Oral SGLT-1&2 inhibitor Type 2 Diabetes | ||||
| R | cemiplimab(**) PD-1 inhibitor mAb Advanced Basal Cell Carcinoma | SP0173 Tdap booster US Tdap booster | sarilumab(**) Anti-IL6R mAb Polymyalgia Rheumatica | Cerdelga® eliglustat Gaucher Type 1, switch from ERT - Pediatric | |||
| isatuximab + cemiplimab(**) Anti-CD38 mAb + PD-1 inhibitor mAb Relapsing Refractory MM | cemiplimab(**) PD-1 inhibitor mAb 1L NSCLC | Praluent®(**) alirocumab LDL-C reduction - Pediatric | |||||
| isatuximab + cemiplimab(**) Anti-CD38 mAb + PD-1 inhibitor mAb Advanced Malignancies | cemiplimab(**)+ chemotherapy PD-1 inhibitor mAb 1L NSCLC | Fluzone® QIV HD Quadrivalent inactivated Influenza vaccine - High dose | |||||
| isatuximab + cemiplimab(**) Anti-CD38 mAb + PD-1 inhibitor mAb Lymphoma | cemiplimab(**) PD-1 inhibitor mAb 2L Cervical Cancer | Men Quad TT Advanced generation meningococcal ACYW conjugate vaccine | |||||
| isatuximab Anti-CD38 mAb 1L Newly Diagnosed MM Ti(5) (IMROZ) | Pediatric pentavalent vaccine DTP-Polio-Hib Japan | ||||||
| Shan 6 DTP-HepB-Polio-Hib Pediatric hexavalent vaccine | |||||||
| Regeneron product for which Sanofi has opt-in rights Also known as BIVV009 Also known as DNL747 Receptor-interacting serine/threonine-protein kinase 1 Transplant ineligible Transplant eligible (*) Phase of projects determined by clinicaltrials.gov disclosure timing (**) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products |
Expected Submission Timeline(1)
| New Molecular Entities | Additional Indications | |||
| 2019(2) | isatuximab anti-CD38 mAb 3L RRMM (ICARIA) | dupilumab(**) Anti-IL4Ra mAb Nasal Polyposis Adult | Pentacel® vIPV DTaP-IPV/Hib | |
| SAR341402 Rapid acting insulin Type 1/2 Diabetes - EU(3) | Fluzone® QIV HD Quadrivalent inactivated Influenza vaccine - High dose | Men Quad TT Adv. generation meningococcal U.S.: 2y+ & EU: Toddlers+ | ||
| 2020(2) | olipudase alfa rhASM ASD(4) | fitusiran RNAi therapeutic targeting anti-thrombin Hemophilia A/B | sarilumab(**) Anti-IL6R mAb Polyarticular Juvenile Idiopathic Arthritis | isatuximab Anti-CD38 mAb 1-3L RRMM (IKEMA) |
| avalglucosidase alfa NeoGAA Pompe Disease | sutimlimab(5) Anti Complement C1s mAb Cold Agglutinin Disease | Dupixent®(**) dupilumab AD 6 - 11 years old | ZynquistaTM(**) Oral SGLT-1&2 inhibitor Type 2 Diabetes | |
| | cemiplimab(**) PD-1 inhibitor mAb Advanced BCC | Aubagio® teriflunomide Relapsing MS - Pediatric | ||
| Shan 6 DTP-HepB-Polio-Hib Pediatric hexavalent vaccine | ||||
| 2021(2) | efpeglenatide(**) Long acting GLP1-R agonist Type 2 Diabetes | isatuximab Anti-CD38 mAb 1L Newly Diagnosed MM Ti (IMROZ) | ZynquistaTM(**) Oral SGLT 1/2 inhibitor Worsening Heart Failure in Diabetes | |
| venglustat Oral GCS inhibitor ADPKD(6) | cemiplimab(**) PD-1 inhibitor mAb 2L Cervical Cancer | |||
| cemiplimab(**) PD-1 inhibitor mAb 1L NSCLC | ||||
| New Molecular Entities | Additional Indications | |||
| 2022(2) | SP0232 mAbs(7)(**) Respiratory Syncytial Virus | Dupixent®(**) dupilumab AD 6 months - 5 years old | sarilumab(**) Anti-IL6R mAb Systemic Juvenile Arthritis | |
| dupilumab(**) Anti-IL4Ra mAb Eosinophilic Esophagitis | sarilumab(**) Anti-IL6R mAb Polymyalgia Rheumatica | |||
| dupilumab(**) Anti-IL4Ralpha mAb Asthma 6 - 11 years old | Cerdelga® eliglustat Gaucher Type 1, switch from ERT Pediatric | |||
| sarilumab(**) Anti-IL6R mAb Giant Cell Arteritis | venglustat Oral GCS inhibitor Gaucher Type 3 | |||
| SP0173 Tdap booster US Tdap booster | Praluent®(**) alirocumab LDL-C reduction - Pediatric | |||
| 2023 and beyond(2) | SAR440340(**) Anti-IL33 mAb Atopic Dermatitis | SAR156597 IL4/IL13 bispecific mAb Systemic Scleroderma | SAR440340(**) Anti-IL33 mAb COPD | dupilumab(**) + AR101 Anti-IL4Ralpha mAb Peanut Allergy - Pediatric |
| SAR422459(**) ABCA4 gene therapy Stargardt Disease | HIV Viral vector prime & rgp120 boost vaccine | SAR440340(**) Anti-IL33 mAb Asthma | venglustat Oral GCS inhibitor Fabry Disease | |
| isatuximab Anti-CD38 mAb Newly Diagnosed MM Te (GMMG) | Rabies VRVg Purified vero rabies vaccine | |||
| venglustat Oral GCS inhibitor GrPD(8) | Pediatric pentavalent vaccine DTP-Polio-Hib (Japan) | |||
- Excluding Phase 1
- Projects within a specified year are not arranged by submission timing
- Submission strategy for the U.S. under evaluation
- Acid Sphingomyelinase Deficiency
- Also known as BIVV009
- Autosomal Dominant Polycystic Kidney Disease
- Also known as MEDI8897
- Gaucher Related Parkinson's Disease
(**) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products
Pipeline Movements Since Q3 2018
| Additions | Removals | ||||||
| Registration | | ||||||
| Phase 3 | Shan 6 DTP-HepB-Polio-Hib Pediatric hexavalent vaccine | mavacamten(**) Myosin inhibitor Obstructive Hypertrophic Cardiomyopathy | cemiplimab(**)+ ipilimumab PD-1 inh. mAb + CTLA4 mAb 1L NSCLC >= 50% PDL1+ | ||||
| Phase 2 | SAR440340(**) Anti-IL33 mAb Atopic Dermatitis | isatuximab + atezolizumab(**) Anti-CD38 mAb + PD-L1 inhibitor mAb Solid Tumors | GZ389988 TRKA antagonist Osteoarthritis | SAR425899 GLP-1/GCG dual agonist Obesity/Overweight in T2D | |||
| isatuximab + cemiplimab(**) Anti-CD38 mAb + PD-1 inhibitor mAb Lymphoma | Combination ferroquine / OZ439(**) Antimalarial | SAR407899 rho kinase Microvascular Angina | |||||
| ALX0171 Anti RSV Nanobody Respiratory Syncitial Virus | mavacamten(**) Myosin inhibitor Non -Obstructive Hypertrophic Cardiomyopathy | ||||||
| Phase 1 | SAR441344 Anti-CD40L mAb Multiple Sclerosis | SAR443060 RIPK1 inh Amyotrophic Lateral Sclerosis | SAR439794(**) TLR4 agonist Peanut Allergy | O | REGN3767 Anti-LAG-3 mAb Advanced Cancers | ||
| O | REGN5458 Anti-BCMA-CD3 bispecific mAb RRMM | SAR443060 RIPK1 inh Alzheimer's Disease | SAR440181(**) Myosin activation Dilated Cardiomyopathy | O | REGN4659 Anti-CTLA-4 mAb Cancer | ||
| SAR441000 Cytokine mRNA Melanoma | BIVV003 ZFN Gene Editing Technology Sickle Cell Disease | SAR247799 S1P1 agonist Cardiovascular indication | SAR228810(**) Anti-protofibrillar AB mAb Alzheimer's Disease | ||||
| Next Gen PCV Pneumococcal Conjugate Vaccines | SAR438335 GLP-1/GIP dual agonist Type 2 Diabetes | UshStat®(**)(1) Myosin 7A gene therapy Usher Syndrome 1B | |||||
| O | cemiplimab(**) + REGN3767 PD-1 inhibitor mAb + Anti-LAG-3 mAb Advanced Cancers | O | cemiplimab(**) + REGN4659 PD-1 inhibitor mAb + Anti-CTLA-4 mAb NSCLC | ||||
(**) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products
Appendix 9: Expected R&D milestones
| Products | Expected milestones | Timing |
| Dupixent® | U.S. regulatory decision in Atopic Dermatitis in Adolescent patients | Q1 2019 |
| ZynquistaTM (sotagliflozin) | U.S. regulatory decision expected in Type 1 Diabetes | Q1 2019 |
| dupilumab | U.S. sBLA filing in Nasal Polyposis | Q1 2019 |
| Dupixent® | EU regulatory decision in Asthma in Adult/Adolescent patients | Q2 2019 |
| ZynquistaTM (sotagliflozin) | EU regulatory decision expected in Type 1 Diabetes | Q2 2019 |
| Praluent® | EU regulatory decision in CV events reduction ODYSSEY OUTCOMES | Q2 2019 |
| Praluent® | U.S. regulatory decision in CV events reduction ODYSSEY OUTCOMES | Q2 2019 |
| cemiplimab | EU regulatory decision expected in Advanced Cutaneous Squamous Cell Carcinoma | Q2 2019 |
| dupilumab | Start of Phase 2b/3 trial in Chronic Obstructive Pulmonary Disease | H1 2019 |
| Dupixent® | EU regulatory decision in Atopic Dermatitis in Adolescent patients | Q3 2019 |
| sutimlimab | Expected pivotal trial read-outs in Cold Agglutinin Disease | Q4 2019 |
| ZynquistaTM (sotagliflozin) | Expected pivotal trial read-out in Type 2 Diabetes | Q4 2019 |
| Dupixent® | Expected pivotal trial read-out in Atopic Dermatitis in 6-11 years | Q4 2019 |
| Olipudase | Expected pivotal trial read-out in Niemann Pick Type B | Q4 2019 |
| Isatuximab | Expected pivotal trial read-out in 1-3L RRMM (IKEMA) | Q1 2020 |
Appendix 10: Definitions of non-GAAP financial indicators
Company
"Company" corresponds to Sanofi and its subsidiaries
Company sales at constant exchange rates (CER)
When we refer to changes in our net sales "at constant exchange rates" (CER), this means that we exclude the effect of changes in exchange rates.
We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period.
Reconciliation of net sales to Company sales at constant exchange rates for the fourth quarter and full-year 2018
| € million | Q4 2018 | 2018 |
| Net sales | 8,997 | 34,463 |
| Effect of exchange rates | (33) | (1,492) |
| Company sales at constant exchange rates | 9,030 | 35,955 |
Business net income
Sanofi publishes a key non-GAAP indicator.
Business net income is defined as net income attributable to equity holders of Sanofi excluding:
- amortization of intangible assets,
- impairment of intangible assets,
- fair value remeasurement of contingent consideration related to business combinations or to disposals,
- other impacts associated with acquisitions (including impacts of acquisitions on associates and joint ventures),
- restructuring costs and similar items(1),
- other gains and losses (including gains and losses on disposals of non-current assets(1)),
- costs or provisions associated with litigation(1),
- tax effects related to the items listed above as well as effects of major tax disputes,
- net income attributable to non-controlling interests related to the items listed above.
- Reported in the line items Restructuring costs and similar items and Gains and losses on disposals, and litigation, which are defined in Notes B.19 and B.20. to our consolidated financial statements.
Attachment
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
